<?xml version="1.0" encoding="UTF-8"?>
<html><body class="spl" id="spl">
<div class="DocumentTitle"><p class="DocumentTitle"><strong>VIORELE- desogestrel and ethinyl estradiol and ethinyl estradiol 
			 </strong><br>Glenmark Generics Inc., USA<br></p></div>
<h1><span class="Bold">VIORELE (Desogestrel and Ethinyl Estradiol Tablets USP, 0.15 mg/0.02 mg and Ethinyl Estradiol Tablets USP, 0.01 mg)</span></h1>
<div class="Contents">
<div class="Section" data-sectionCode="48780-1">
<a name="section-1"></a><p></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_6559eb72-0dba-407f-b0cb-9bec0897fa9d"></a><a name="section-1"></a><p></p>
<p class="First"><span class="Bold">Rx only</span></p>
<p><span class="Bold">Patients should be counseled that this product does not protect against <span class="product-label-link" type="condition" conceptid="439727" conceptname="Human immunodeficiency virus infection">HIV infection</span> (AIDS) and other <span class="product-label-link" type="condition" conceptid="440647" conceptname="Sexually transmitted infectious disease">sexually transmitted diseases</span>.</span></p>
</div>
<div class="Section" data-sectionCode="34089-3">
<a name="i4i_description_id_78cfbc09-eaa6-4342-b2ae-ca31f88c0011"></a><a name="section-2"></a><p></p>
<h1>DESCRIPTION</h1>
<p class="First">VIORELE (desogestrel and ethinyl estradiol tablets USP and ethinyl estradiol tablets USP)  provides an oral contraceptive regimen of 21 white, round tablets each containing 0.15 mg desogestrel (13-ethyl-11- methylene-18,19-dinor-17 alpha-pregn- 4-en- 20-yn-17-ol), 0.02 mg ethinyl estradiol USP (19-nor-17 alpha-pregna-1,3,5 (10)-trien-20-yne-3,17-diol), and inactive ingredients which include vitamin E, potato starch, povidone, isopropyl alcohol, colloidal silicon dioxide, magnesium stearate, lactose, hypromellose, titanium dioxide, macrogol, talc, followed by 2 inert green, round tablets with the following inactive ingredients: lactose, starch, magnesium stearate, hypromellose, titanium dioxide, macrogol, talc, iron oxide yellow, FD&amp;C blue No. 2 indigo carmine aluminum lake. VIORELE also contains 5 yellow, round tablets containing 0.01 mg ethinyl estradiol USP (19-nor-17 alpha-pregna-1,3,5 (10)-trien-20-yne-3, 17-diol) and inactive ingredients which include vitamin E, lactose, potato starch, povidone, isopropyl alcohol, colloidal silicon dioxide, magnesium stearate, hypromellose, titanium dioxide, macrogol, talc, iron oxide yellow. The molecular weights for desogestrel and ethinyl estradiol USP are 310.48 and 296.40 respectively. The structural formulas are as follows:</p>
<div class="Figure">
<a name="id504"></a><img alt="desogestrel chemical structure and ethinyl estradiol chemical structure" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=39988aa6-8f68-40e8-9bdd-c40a3bdaad61&amp;name=644dec7a-1c0d-4161-a454-e280023f5735-01.jpg">
</div>
</div>
<div class="Section" data-sectionCode="34090-1">
<a name="i4i_clinical_pharmacology_id_3e7daed9-636b-4c4a-ad4a-432a6fd7a48e"></a><a name="section-3"></a><p></p>
<h1>CLINICAL PHARMACOLOGY</h1>
<p class="First">Combination oral contraceptives act by suppression of gonadotropins. Although the primary mechanism of this action is inhibition of ovulation, other alterations include changes in the cervical mucus (which increase the difficulty of sperm entry into the uterus) and the endometrium (which reduce the likelihood of implantation).</p>
<p>Receptor binding studies, as well as studies in animals, have shown that etonogestrel, the biologically active metabolite of desogestrel, combines high progestational activity with minimal intrinsic androgenicity (91, 92). The relevance of this latter finding in humans is unknown.</p>
<div class="Section" data-sectionCode="43682-4">
<a name="i4i_pharmacokinetics_id_1906336b-1c5e-40d0-8cfe-44df6c563f1f"></a><a name="section-3.1"></a><p></p>
<h2>Pharmacokinetics</h2>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_056ccd53-7a19-408a-8c4a-a22f3d29b1ca"></a><a name="section-3.1.1"></a><p></p>
<h3>Absorption</h3>
<p class="First">Desogestrel is rapidly and almost completely absorbed and converted into etonogestrel, its biologically active metabolite. Following oral administration, the relative bioavailability of desogestrel compared to a solution, as measured by serum levels of etonogestrel, is approximately 100%. VIORELE provides two different regimens of ethinyl estradiol; 0.02 mg in the combination tablet [white] as well as 0.01 mg in the yellow tablet. Ethinyl estradiol is rapidly and almost completely absorbed. After a single dose of VIORELE combination tablet [white], the relative bioavailability of ethinyl estradiol is approximately 93% while the relative bioavailability of the 0.01 mg tablet [yellow] is 99%. The effect of food on the bioavailability of VIORELE following oral administration has not been evaluated.</p>
<p>The pharmacokinetics of etonogestrel and ethinyl estradiol following multiple dose administration of desogestrel/ethinyl estradiol and ethinyl estradiol tablets were determined during the third cycle in 17 subjects. Plasma concentrations of etonogestrel and ethinyl estradiol reached steady-state by Day 21. The AUC<span class="Sub">(0-24)</span> for etonogestrel at steady-state on Day 21 was approximately 2.2 times higher than AUC<span class="Sub">(0-24)</span> on Day 1 of the third cycle. The pharmacokinetic parameters of etonogestrel and ethinyl estradiol during the third cycle following multiple dose administration of desogestrel/ethinyl estradiol and ethinyl estradiol tablets are summarized in Table I.</p>
<a name="_RefIDDEB778FF05AC4E088732F753C54E9820"></a><table>
<caption><span>TABLE I: MEAN (SD) PHARMACOKINETIC PARAMETERS OF DESOGESTREL/ETHINYL ESTRADIOL AND ETHINYL ESTRADIOL OVER A 28-DAY DOSING PERIOD IN THE THIRD CYCLE (n=17). </span></caption>
<col width="7%">
<col width="9%">
<col width="20%">
<col width="12%">
<col width="15%">
<col width="23%">
<col width="15%">
<tbody class="Headless">
<tr class="First"><td class="Botrule Lrule Rrule Toprule" colspan="7" valign="top"><p class="First"><span class="Bold">Etonogestrel</span></p></td></tr>
<tr>
<td class="Botrule Lrule" valign="top"><p class="First">Day</p></td>
<td class="Botrule Lrule" valign="top">
<p class="First">Dose<span class="Sup">a</span></p>
<p>mg</p>
</td>
<td class="Botrule Lrule" valign="top">
<p class="First">C<span class="Sub">max</span></p>
<p> pg/mL</p>
</td>
<td class="Botrule Lrule" valign="top">
<p class="First">T<span class="Sub">max</span></p>
<p> h</p>
</td>
<td class="Botrule Lrule" valign="top">
<p class="First">t<span class="Sub">½ </span></p>
<p>h</p>
</td>
<td class="Botrule Lrule" valign="top"><p class="First">AUC<span class="Sub">0-24 </span>pg/mL•hr</p></td>
<td class="Botrule Lrule Rrule" valign="top">
<p class="First">CL/F</p>
<p> L/h</p>
</td>
</tr>
<tr>
<td class="Botrule Lrule" valign="top"><p class="First">1</p></td>
<td class="Botrule Lrule" valign="top"><p class="First">0.15</p></td>
<td class="Botrule Lrule" valign="top"><p class="First">2503.6 (987.6)</p></td>
<td class="Botrule Lrule" valign="top"><p class="First">2.4 (1.0)</p></td>
<td class="Botrule Lrule" valign="top"><p class="First">29.8 (16.3)</p></td>
<td class="Botrule Lrule" valign="top"><p class="First">17,832 (5674)</p></td>
<td class="Botrule Lrule Rrule" valign="top"><p class="First">5.4 (2.5)</p></td>
</tr>
<tr>
<td class="Botrule Lrule" valign="top"><p class="First">21</p></td>
<td class="Botrule Lrule" valign="top"><p class="First">0.15</p></td>
<td class="Botrule Lrule" valign="top"><p class="First">4091.2 (1186.2)</p></td>
<td class="Botrule Lrule" valign="top"><p class="First">1.6 (0.7)</p></td>
<td class="Botrule Lrule" valign="top"><p class="First">27.8 (7.2)</p></td>
<td class="Botrule Lrule" valign="top"><p class="First">39,391 (12,134)</p></td>
<td class="Botrule Lrule Rrule" valign="top"><p class="First">4.4 (1.4)</p></td>
</tr>
<tr><td class="Botrule Lrule Rrule" colspan="7" valign="top"><p class="First"><span class="Sup">a</span> Desogestrel</p></td></tr>
<tr><td class="Botrule Lrule Rrule" colspan="7" valign="top"><p class="First"><span class="Bold">Ethinyl Estradiol </span></p></td></tr>
<tr>
<td class="Botrule Lrule" valign="top"><p class="First">Day</p></td>
<td class="Botrule Lrule" valign="top">
<p class="First">Dose</p>
<p> mg</p>
</td>
<td class="Botrule Lrule" valign="top">
<p class="First">C<span class="Sub">max</span></p>
<p>pg/mL</p>
</td>
<td class="Botrule Lrule" valign="top">
<p class="First">T<span class="Sub">max</span></p>
<p>h</p>
</td>
<td class="Botrule Lrule" valign="top">
<p class="First">t<span class="Sub">½</span></p>
<p>h</p>
</td>
<td class="Botrule Lrule" valign="top"><p class="First">AUC<span class="Sub">0-24</span> pg/mL•hr</p></td>
<td class="Botrule Lrule Rrule" valign="top">
<p class="First">CL/F </p>
<p>L/h</p>
</td>
</tr>
<tr>
<td class="Botrule Lrule" valign="top"><p class="First">1</p></td>
<td class="Botrule Lrule" valign="top"><p class="First">0.02</p></td>
<td class="Botrule Lrule" valign="top"><p class="First">51.9 (15.4)</p></td>
<td class="Botrule Lrule" valign="top"><p class="First">2.9 (1.2)</p></td>
<td class="Botrule Lrule" valign="top"><p class="First">16.5 (4.8)</p></td>
<td class="Botrule Lrule" valign="top"><p class="First">566 (173)<span class="Sup">a</span></p></td>
<td class="Botrule Lrule Rrule" valign="top"><p class="First">25.7 (9.1)</p></td>
</tr>
<tr>
<td class="Botrule Lrule" valign="top"><p class="First">21</p></td>
<td class="Botrule Lrule" valign="top"><p class="First">0.02</p></td>
<td class="Botrule Lrule" valign="top"><p class="First">62.2 (25.9)</p></td>
<td class="Botrule Lrule" valign="top"><p class="First">2.0 (0.8)</p></td>
<td class="Botrule Lrule" valign="top"><p class="First">23.9 (25.5)</p></td>
<td class="Botrule Lrule" valign="top"><p class="First">597 (127)<span class="Sup">a</span></p></td>
<td class="Botrule Lrule Rrule" valign="top"><p class="First">35.1 (8.2)</p></td>
</tr>
<tr>
<td class="Botrule Lrule" valign="top"><p class="First">24</p></td>
<td class="Botrule Lrule" valign="top"><p class="First">0.01</p></td>
<td class="Botrule Lrule" valign="top"><p class="First">24.6 (10.8)</p></td>
<td class="Botrule Lrule" valign="top"><p class="First">2.4 (1.0)</p></td>
<td class="Botrule Lrule" valign="top"><p class="First">18.8 (10.3)</p></td>
<td class="Botrule Lrule" valign="top"><p class="First">246 (65)</p></td>
<td class="Botrule Lrule Rrule" valign="top"><p class="First">43.6 (12.2)</p></td>
</tr>
<tr class="Last">
<td class="Botrule Lrule" valign="top"><p class="First">28</p></td>
<td class="Botrule Lrule" valign="top"><p class="First">0.01</p></td>
<td class="Botrule Lrule" valign="top"><p class="First">35.3 (27.5)</p></td>
<td class="Botrule Lrule" valign="top"><p class="First">2.1 (1.3)</p></td>
<td class="Botrule Lrule" valign="top"><p class="First">18.9 (8.3)</p></td>
<td class="Botrule Lrule" valign="top"><p class="First">312 (62)</p></td>
<td class="Botrule Lrule Rrule" valign="top"><p class="First">33.2 (6.6)</p></td>
</tr>
</tbody>
</table>
<p><span class="Sup">a</span> n=16</p>
<p>C<span class="Sub">max</span> - measured peak concentration <br>T<span class="Sub">max </span>- observed time of peak concentration <br>t<span class="Sub">½</span> - elimination half-life, calculated by 0.693/Kelim<br>AUC<span class="Sub">0-24</span> - area under the concentration-time curve calculated by the linear trapezoidal rule (Time 0 to 24 hours) <br>CL/F - apparent clearance</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_5897ff81-c683-453b-bd5d-e40cfaba814b"></a><a name="section-3.1.2"></a><p></p>
<h3>Distribution</h3>
<p class="First">Etonogestrel, the active metabolite of desogestrel, was found to be 99% protein bound, primarily to sex hormone-binding globulin (SHBG). Ethinyl estradiol is approximately 98.3% bound, mainly to plasma albumin. Ethinyl estradiol does not bind to SHBG, but induces SHBG synthesis. Desogestrel, in combination with ethinyl estradiol, does not counteract the estrogen-induced increase in SHBG, resulting in lower serum levels of free testosterone (96-99).</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_c436a1e3-1212-4629-9622-99ae2911dda5"></a><a name="section-3.1.3"></a><p></p>
<h3>Metabolism</h3>
<p class="First"><span class="Italics">Desogestrel: </span>Desogestrel is rapidly and completely metabolized by hydroxylation in the intestinal mucosa and on first pass through the liver to etonogestrel. Other metabolites (i.e., 3<span class="Italics">α</span>-OH-desogestrel, 3<span class="Italics">β</span>-OH-desogestrel, and 3<span class="Italics">α</span>-OH-5<span class="Italics">α</span>-H-desogestrel) with no pharmacologic actions also have been identified and these metabolites may undergo glucuronide and sulfate conjugation.</p>
<p><span class="Italics">Ethinyl estradiol: </span>Ethinyl estradiol is subject to a significant degree of presystemic conjugation (phase II metabolism). Ethinyl estradiol escaping gut wall conjugation undergoes phase I metabolism and hepatic conjugation (phase II metabolism). Major phase I metabolites are 2-OH-ethinyl estradiol and 2-methoxy-ethinyl estradiol. Sulfate and glucuronide conjugates of both ethinyl estradiol and phase I metabolites, which are excreted in bile, can undergo enterohepatic circulation.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_0fcc5e9b-e2c3-489c-a2ac-b660f642a86d"></a><a name="section-3.1.4"></a><p></p>
<h3>Excretion</h3>
<p class="First">Etonogestrel and ethinyl estradiol are excreted in urine, bile, and feces. At steady state, on Day 21, the elimination half-life of etonogestrel is 27.8±7.2 hours and the elimination half-life of ethinyl estradiol for the combination tablet is 23.9±25.5 hours. For the 0.01 mg ethinyl estradiol tablet [yellow], the elimination half-life at steady state, Day 28, is 18.9±8.3 hours.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_ca17017e-a4ba-484d-a386-c9fe3b9f3be7"></a><a name="section-3.1.5"></a><p></p>
<h3>Special Populations</h3>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_f30532e3-ef54-49d0-88df-ad76bbc1b177"></a><a name="section-3.1.5.1"></a><p></p>
<h4>Race</h4>
<p class="First">There is no information to determine the effect of race on the pharmacokinetics of VIORELE. </p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_82a5d167-d59d-4bc0-9c63-f9ebb4a95056"></a><a name="section-3.1.5.2"></a><p></p>
<h4><span class="product-label-link" type="condition" conceptid="4245975" conceptname="Hepatic failure">Hepatic Insufficiency</span> </h4>
<p class="First">No formal studies were conducted to evaluate the effect of <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic disease</span> on the disposition of desogestrel/ethinyl estradiol and ethinyl estradiol.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_1f07371f-620b-452a-bc87-257e217d1b55"></a><a name="section-3.1.5.3"></a><p></p>
<h4><span class="product-label-link" type="condition" conceptid="192359" conceptname="Renal failure syndrome">Renal Insufficiency</span></h4>
<p class="First">No formal studies were conducted to evaluate the effect of <span class="product-label-link" type="condition" conceptid="198124" conceptname="Kidney disease">renal disease</span> on the disposition of desogestrel/ethinyl estradiol and ethinyl estradiol.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_e85aea76-3bff-4699-b30f-6b5c2603d027"></a><a name="section-3.1.5.4"></a><p></p>
<h4>Drug-Drug Interactions</h4>
<p class="First">Interactions between desogestrel/ethinyl estradiol and other drugs have been reported in the literature. No formal drug-drug interaction studies were conducted (see <span class="Bold"><a href="#i4i_precautions_id_bc3885a3-3935-4a6f-b3b3-7a691dd216b3">PRECAUTIONS</a></span> section).</p>
</div>
</div>
</div>
</div>
<div class="Section" data-sectionCode="34067-9">
<a name="i4i_indications_id_9ab292f2-8eb4-40fc-9870-c74f127ae1b1"></a><a name="section-4"></a><p></p>
<h1>INDICATIONS AND USAGE</h1>
<p class="First">VIORELE (desogestrel and ethinyl estradiol tablets USP and ethinyl estradiol tablets USP) is indicated for the prevention of pregnancy in women who elect to use this product as a method of contraception.</p>
<p>Oral contraceptives are highly effective. Table II lists the typical accidental pregnancy rates for users of combination oral contraceptives and other methods of contraception. The efficacy of these contraceptive methods, except sterilization, depends upon the reliability with which they are used. Correct and consistent use of these methods can result in lower failure rates.</p>
<a name="_RefIDD83F23CC0AC2465E8EB58DE91366D6E8"></a><table>
<caption><span>TABLE II: Percentage of women experiencing an <span class="product-label-link" type="condition" conceptid="4307820" conceptname="Unplanned pregnancy">unintended pregnancy</span> during the first year of typical use and the first year of perfect use of contraception and the percentage continuing use at the end of the first year, United States. </span></caption>
<col width="20%">
<col width="26%">
<col width="25%">
<col width="29%">
<tfoot><tr><td colspan="4" align="left"><dl class="Footnote">
<dt><a name="footnote-1" href="#footnote-reference-1">*</a></dt>
<dd>Among couples attempting to avoid pregnancy, the percentage who continue to use a method for one year.</dd>
<dt><a name="footnote-2" href="#footnote-reference-2">†</a></dt>
<dd>Among <span class="Italics">typical </span>couples who initiate use of a method (not necessarily for the first time), the percentage who experience an accidental pregnancy during the first year if they do not stop use for any other reason.</dd>
<dt><a name="footnote-3" href="#footnote-reference-3">‡</a></dt>
<dd>Among couples who initiate use of a method (not necessarily for the first time) and who use it <span class="Italics">perfectly </span>(both consistently and correctly), the percentage who experience an accidental pregnancy during the first year if they do not stop use for any other reason.</dd>
<dt><a name="footnote-4" href="#footnote-reference-4">§</a></dt>
<dd>The percents becoming pregnant in columns (2) and (3) are based on data from populations where contraception is not used and from women who cease using contraception in order to become pregnant. Among such populations, about 89% become pregnant within one year. This estimate was lowered slightly (to 85%) to represent the percent who would become pregnant within one year among women now relying on reversible methods of contraception if they abandoned contraception altogether.</dd>
<dt><a name="footnote-5" href="#footnote-reference-5">¶</a></dt>
<dd>Foams, creams, gels, vaginal suppositories, and vaginal film.</dd>
<dt><a name="footnote-6" href="#footnote-reference-6">#</a></dt>
<dd>Cervical mucus (ovulation) method supplemented by calendar in the pre-ovulatory and basal body temperature in the post-ovulatory phases.</dd>
<dt><a name="footnote-7" href="#footnote-reference-7">Þ</a></dt>
<dd>With spermicidal cream or jelly.</dd>
<dt><a name="footnote-8" href="#footnote-reference-8">ß</a></dt>
<dd>Without spermicides.</dd>
</dl></td></tr></tfoot>
<tbody class="Headless">
<tr class="First">
<td class="Botrule Lrule Toprule" valign="top"></td>
<td class="Botrule Lrule Toprule" align="center" colspan="2" valign="top"><p class="First"><span class="Bold">% of Women Experiencing an <span class="product-label-link" type="condition" conceptid="4307820" conceptname="Unplanned pregnancy">Unintended Pregnancy</span> within the First Year of Use</span></p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><p class="First"><span class="Bold">% of Women Continuing Use at One Year</span><a name="footnote-reference-1" href="#footnote-1" class="Sup">*</a></p></td>
</tr>
<tr>
<td class="Botrule Lrule" valign="top"><p class="First"><span class="Bold">Method</span><br><span class="Bold">(1)</span></p></td>
<td class="Botrule Lrule" align="center" valign="top"><p class="First"><span class="Bold">Typical Use</span><a name="footnote-reference-2" href="#footnote-2" class="Sup">†</a><br><span class="Bold">(2)</span></p></td>
<td class="Botrule Lrule" align="center" valign="top"><p class="First"><span class="Bold">Perfect Use</span><a name="footnote-reference-3" href="#footnote-3" class="Sup">‡</a><br><span class="Bold">(3)</span></p></td>
<td class="Botrule Lrule Rrule" align="center" valign="top"><p class="First"><span class="Bold">(4)</span></p></td>
</tr>
<tr>
<td class="Botrule Lrule" valign="top"><p class="First">Chance<a name="footnote-reference-4" href="#footnote-4" class="Sup">§</a></p></td>
<td class="Botrule Lrule" align="center" valign="top"><p class="First">85</p></td>
<td class="Botrule Lrule" align="center" valign="top"><p class="First">85</p></td>
<td class="Botrule Lrule Rrule" valign="top"></td>
</tr>
<tr>
<td class="Botrule Lrule" valign="top"><p class="First">Spermicides<a name="footnote-reference-5" href="#footnote-5" class="Sup">¶</a></p></td>
<td class="Botrule Lrule" align="center" valign="top"><p class="First">26</p></td>
<td class="Botrule Lrule" align="center" valign="top"><p class="First">6</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="top"><p class="First">40</p></td>
</tr>
<tr>
<td class="Botrule Lrule" valign="top"><p class="First">Periodic abstinence</p></td>
<td class="Botrule Lrule" align="center" valign="top"><p class="First">25</p></td>
<td class="Botrule Lrule" valign="top"></td>
<td class="Botrule Lrule Rrule" align="center" valign="top"><p class="First">63</p></td>
</tr>
<tr>
<td class="Botrule Lrule" valign="top"><p class="First">Calendar</p></td>
<td class="Botrule Lrule" valign="top"></td>
<td class="Botrule Lrule" align="center" valign="top"><p class="First">9</p></td>
<td class="Botrule Lrule Rrule" valign="top"></td>
</tr>
<tr>
<td class="Botrule Lrule" valign="top"><p class="First">Ovulation Method</p></td>
<td class="Botrule Lrule" valign="top"></td>
<td class="Botrule Lrule" align="center" valign="top"><p class="First">3</p></td>
<td class="Botrule Lrule Rrule" valign="top"></td>
</tr>
<tr>
<td class="Botrule Lrule" valign="top"><p class="First">Sympto-Thermal<a name="footnote-reference-6" href="#footnote-6" class="Sup">#</a></p></td>
<td class="Botrule Lrule" valign="top"></td>
<td class="Botrule Lrule" align="center" valign="top"><p class="First">2</p></td>
<td class="Botrule Lrule Rrule" valign="top"></td>
</tr>
<tr>
<td class="Botrule Lrule" valign="top"><p class="First">Post-Ovulation</p></td>
<td class="Botrule Lrule" valign="top"></td>
<td class="Botrule Lrule" align="center" valign="top"><p class="First">1</p></td>
<td class="Botrule Lrule Rrule" valign="top"></td>
</tr>
<tr>
<td class="Botrule Lrule" valign="top"><p class="First">Withdrawal</p></td>
<td class="Botrule Lrule" align="center" valign="top"><p class="First">19</p></td>
<td class="Botrule Lrule" align="center" valign="top"><p class="First">4</p></td>
<td class="Botrule Lrule Rrule" valign="top"></td>
</tr>
<tr>
<td class="Botrule Lrule" valign="top"><p class="First"><span class="Bold">Cap</span><a name="footnote-reference-7" href="#footnote-7" class="Sup">Þ</a></p></td>
<td class="Botrule Lrule" valign="top"></td>
<td class="Botrule Lrule" valign="top"></td>
<td class="Botrule Lrule Rrule" valign="top"></td>
</tr>
<tr>
<td class="Botrule Lrule" valign="top"><p class="First">Parous Women</p></td>
<td class="Botrule Lrule" align="center" valign="top"><p class="First">40</p></td>
<td class="Botrule Lrule" align="center" valign="top"><p class="First">26</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="top"><p class="First">42</p></td>
</tr>
<tr>
<td class="Botrule Lrule" valign="top"><p class="First">Nulliparous Women</p></td>
<td class="Botrule Lrule" align="center" valign="top"><p class="First">20</p></td>
<td class="Botrule Lrule" align="center" valign="top"><p class="First">9</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="top"><p class="First">56</p></td>
</tr>
<tr>
<td class="Botrule Lrule" valign="top"><p class="First"><span class="Bold">Sponge</span></p></td>
<td class="Botrule Lrule" valign="top"></td>
<td class="Botrule Lrule" valign="top"></td>
<td class="Botrule Lrule Rrule" valign="top"></td>
</tr>
<tr>
<td class="Botrule Lrule" valign="top"><p class="First">Parous Women</p></td>
<td class="Botrule Lrule" align="center" valign="top"><p class="First">40</p></td>
<td class="Botrule Lrule" align="center" valign="top"><p class="First">20</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="top"><p class="First">42</p></td>
</tr>
<tr>
<td class="Botrule Lrule" valign="top"><p class="First">Nulliparous Women</p></td>
<td class="Botrule Lrule" align="center" valign="top"><p class="First">20</p></td>
<td class="Botrule Lrule" align="center" valign="top"><p class="First">9</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="top"><p class="First">56</p></td>
</tr>
<tr>
<td class="Botrule Lrule" valign="top"><p class="First">Diaphragm<a href="#footnote-7" class="Sup">Þ</a></p></td>
<td class="Botrule Lrule" align="center" valign="top"><p class="First">20</p></td>
<td class="Botrule Lrule" align="center" valign="top"><p class="First">6</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="top"><p class="First">56</p></td>
</tr>
<tr>
<td class="Botrule Lrule" valign="top"><p class="First">Condom<a name="footnote-reference-8" href="#footnote-8" class="Sup">ß</a></p></td>
<td class="Botrule Lrule" valign="top"></td>
<td class="Botrule Lrule" valign="top"></td>
<td class="Botrule Lrule Rrule" valign="top"></td>
</tr>
<tr>
<td class="Botrule Lrule" valign="top"><p class="First">Female (Reality)</p></td>
<td class="Botrule Lrule" align="center" valign="top"><p class="First">21</p></td>
<td class="Botrule Lrule" align="center" valign="top"><p class="First">5</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="top"><p class="First">56</p></td>
</tr>
<tr>
<td class="Botrule Lrule" valign="top"><p class="First">Male</p></td>
<td class="Botrule Lrule" align="center" valign="top"><p class="First">14</p></td>
<td class="Botrule Lrule" align="center" valign="top"><p class="First">3</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="top"><p class="First">61</p></td>
</tr>
<tr>
<td class="Botrule Lrule" valign="top"><p class="First">Pill</p></td>
<td class="Botrule Lrule" align="center" valign="top"><p class="First">5</p></td>
<td class="Botrule Lrule" valign="top"></td>
<td class="Botrule Lrule Rrule" align="center" valign="top"><p class="First">71</p></td>
</tr>
<tr>
<td class="Botrule Lrule" valign="top"><p class="First">Progestin Only</p></td>
<td class="Botrule Lrule" valign="top"></td>
<td class="Botrule Lrule" align="center" valign="top"><p class="First">0.5</p></td>
<td class="Botrule Lrule Rrule" valign="top"></td>
</tr>
<tr>
<td class="Botrule Lrule" valign="top"><p class="First">Combined</p></td>
<td class="Botrule Lrule" valign="top"></td>
<td class="Botrule Lrule" align="center" valign="top"><p class="First">0.1</p></td>
<td class="Botrule Lrule Rrule" valign="top"></td>
</tr>
<tr>
<td class="Botrule Lrule" valign="top"><p class="First"><span class="Bold">IUD</span></p></td>
<td class="Botrule Lrule" valign="top"></td>
<td class="Botrule Lrule" valign="top"></td>
<td class="Botrule Lrule Rrule" valign="top"></td>
</tr>
<tr>
<td class="Botrule Lrule" valign="top"><p class="First">Progesterone T</p></td>
<td class="Botrule Lrule" align="center" valign="top"><p class="First">2.0</p></td>
<td class="Botrule Lrule" align="center" valign="top"><p class="First">1.5</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="top"><p class="First">81</p></td>
</tr>
<tr>
<td class="Botrule Lrule" valign="top"><p class="First">Copper T 380A</p></td>
<td class="Botrule Lrule" align="center" valign="top"><p class="First">0.8</p></td>
<td class="Botrule Lrule" align="center" valign="top"><p class="First">0.6</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="top"><p class="First">78</p></td>
</tr>
<tr>
<td class="Botrule Lrule" valign="top"><p class="First">LNg 20</p></td>
<td class="Botrule Lrule" align="center" valign="top"><p class="First">0.1</p></td>
<td class="Botrule Lrule" align="center" valign="top"><p class="First">0.1</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="top"><p class="First">81</p></td>
</tr>
<tr>
<td class="Botrule Lrule" valign="top"><p class="First">Depo-Provera</p></td>
<td class="Botrule Lrule" align="center" valign="top"><p class="First">0.3</p></td>
<td class="Botrule Lrule" align="center" valign="top"><p class="First">0.3</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="top"><p class="First">70</p></td>
</tr>
<tr>
<td class="Botrule Lrule" valign="top"><p class="First">Norplant and Norplant-2</p></td>
<td class="Botrule Lrule" align="center" valign="top"><p class="First">0.05</p></td>
<td class="Botrule Lrule" align="center" valign="top"><p class="First">0.05</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="top"><p class="First">88</p></td>
</tr>
<tr>
<td class="Botrule Lrule" valign="top"><p class="First">Female sterilization</p></td>
<td class="Botrule Lrule" align="center" valign="top"><p class="First">0.5</p></td>
<td class="Botrule Lrule" align="center" valign="top"><p class="First">0.5</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="top"><p class="First">100</p></td>
</tr>
<tr class="Last">
<td class="Botrule Lrule" valign="top"><p class="First">Male sterilization</p></td>
<td class="Botrule Lrule" align="center" valign="top"><p class="First">0.15</p></td>
<td class="Botrule Lrule" align="center" valign="top"><p class="First">0.10</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="top"><p class="First">100</p></td>
</tr>
</tbody>
</table>
<p>Adapted from Hatcher et al., 1998, Ref#1.</p>
</div>
<div class="Section" data-sectionCode="34070-3">
<a name="i4i_contraindications_id_2d774397-6f9a-4784-9005-be77b7881ccf"></a><a name="section-5"></a><p></p>
<h1>CONTRAINDICATIONS</h1>
<p class="First">Oral contraceptives should not be used in women who currently have the following conditions:</p>
<dl>
<dt>•</dt>
<dd><span class="product-label-link" type="condition" conceptid="320741" conceptname="Thrombophlebitis">Thrombophlebitis</span> or thromboembolic disorders </dd>
<dt>•</dt>
<dd>A past history of deep vein <span class="product-label-link" type="condition" conceptid="320741" conceptname="Thrombophlebitis">thrombophlebitis</span> or thromboembolic disorders </dd>
<dt>•</dt>
<dd>Cerebral vascular or <span class="product-label-link" type="condition" conceptid="317576" conceptname="Coronary arteriosclerosis">coronary artery disease</span> </dd>
<dt>•</dt>
<dd>Known or suspected carcinoma of the breast </dd>
<dt>•</dt>
<dd>Carcinoma of the endometrium or other known or suspected estrogen-dependent neoplasia </dd>
<dt>•</dt>
<dd>Undiagnosed abnormal genital <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> </dd>
<dt>•</dt>
<dd><span class="product-label-link" type="condition" conceptid="4185719" conceptname="Cholestatic jaundice syndrome">Cholestatic jaundice</span> of pregnancy or <span class="product-label-link" type="condition" conceptid="137977" conceptname="Jaundice">jaundice</span> with prior pill use </dd>
<dt>•</dt>
<dd><span class="product-label-link" type="condition" conceptid="4301500" conceptname="Liver cell adenoma">Hepatic adenomas</span> or carcinomas </dd>
<dt>•</dt>
<dd>Known or suspected pregnancy</dd>
</dl>
</div>
<div class="Section" data-sectionCode="34071-1">
<a name="i4i_warnings_id_7dbb18ea-1b8a-4416-832f-5ac89bec8803"></a><a name="section-6"></a><p></p>
<h1>WARNINGS </h1>
<table>
<col width="100%">
<tbody class="Headless"><tr class="First Last"><td class="Botrule Lrule Rrule Toprule" valign="top"><p class="First"><span class="Bold">Cigarette smoking increases the risk of serious cardiovascular side effects from oral contraceptive use. This risk increases with age and with heavy smoking (15 or more cigarettes per day) and is quite marked in women over 35 years of age. Women who use oral contraceptives should be strongly advised not to smoke.</span></p></td></tr></tbody>
</table>
<p class="First">The use of oral contraceptives is associated with increased risks of several serious conditions including <span class="product-label-link" type="condition" conceptid="4329847" conceptname="Myocardial infarction">myocardial infarction</span>, <span class="product-label-link" type="condition" conceptid="4159647" conceptname="Thromboembolic disorder">thromboembolism</span>, <span class="product-label-link" type="condition" conceptid="381316" conceptname="Cerebrovascular accident">stroke</span>, <span class="product-label-link" type="condition" conceptid="4322895" conceptname="Nodule of liver">hepatic neoplasia</span>, and <span class="product-label-link" type="condition" conceptid="192353" conceptname="Disorder of gallbladder">gallbladder disease</span>, although the risk of serious morbidity or mortality is very small in healthy women without underlying risk factors. The risk of morbidity and mortality increases significantly in the presence of other underlying risk factors such as <span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">hypertension</span>, <span class="product-label-link" type="condition" conceptid="432867" conceptname="Hyperlipidemia">hyperlipidemias</span>, <span class="product-label-link" type="condition" conceptid="433736" conceptname="Obesity">obesity</span>, and <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span>.</p>
<p>Practitioners prescribing oral contraceptives should be familiar with the following information relating to these risks.</p>
<p>The information contained in this package insert is principally based on studies carried out in patients who used oral contraceptives with formulations of higher doses of estrogens and progestogens than those in common use today. The effect of long-term use of the oral contraceptives with formulations of lower doses of both estrogens and progestogens remains to be determined.</p>
<p>Throughout this labeling, epidemiologic studies reported are of two types: retrospective or case control studies and prospective or cohort studies. Case control studies provide a measure of the relative risk of a disease, namely, a <span class="Italics">ratio</span> of the incidence of a disease among oral contraceptive users to that among non-users. The relative risk does not provide information on the actual clinical occurrence of a disease. Cohort studies provide a measure of attributable risk, which is the <span class="Italics">difference</span> in the incidence of disease between oral contraceptive users and non-users. The attributable risk does provide information about the actual occurrence of a disease in the population (Adapted from refs. 2 and 3 with the authors' permission). For further information, the reader is referred to a text on epidemiologic methods.</p>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_1c4b44a5-e805-43db-909a-b8b2011ff1e0"></a><a name="section-6.1"></a><p></p>
<h2>1. Thromboembolic disorders and other vascular problems </h2>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_3936b0e1-ab6a-4c42-a993-bf5f52e5722a"></a><a name="section-6.1.1"></a><p></p>
<h3>a. <span class="product-label-link" type="condition" conceptid="4159647" conceptname="Thromboembolic disorder">Thromboembolism</span></h3>
<p class="First">An increased risk of thromboembolic and thrombotic disease associated with the use of oral contraceptives is well established. Case control studies have found the relative risk of users compared to nonusers to be 3 for the first episode of superficial venous thromboembolic disease, 4 to 11 for <span class="product-label-link" type="condition" conceptid="4042396" conceptname="Deep thrombophlebitis">deep vein thrombosis</span> or <span class="product-label-link" type="condition" conceptid="440417" conceptname="Pulmonary embolism">pulmonary embolism</span>, and 1.5 to 6 for women with predisposing conditions for venous thromboembolic disease (2,3,19-24). Cohort studies have shown the relative risk to be somewhat lower, about 3 for new cases and about 4.5 for new cases requiring hospitalization (25). The risk of thromboembolic disease associated with oral contraceptives is not related to length of use and disappears after pill use is stopped (2).</p>
<p>Several epidemiologic studies indicate that third generation oral contraceptives, including those containing desogestrel, are associated with a higher risk of <span class="product-label-link" type="condition" conceptid="318775" conceptname="Venous embolism">venous thromboembolism</span> than certain second generation oral contraceptives (102-104). In general, these studies indicate an approximate two-fold increased risk, which corresponds to an additional 1 to 2 cases of <span class="product-label-link" type="condition" conceptid="318775" conceptname="Venous embolism">venous thromboembolism</span> per 10,000 women-years of use. However, data from additional studies have not shown this two-fold increase in risk.</p>
<p>A two- to four-fold increase in relative risk of post-operative thromboembolic complications has been reported with the use of oral contraceptives (9, 26). The relative risk of <span class="product-label-link" type="condition" conceptid="444247" conceptname="Venous thrombosis">venous thrombosis</span> in women who have predisposing conditions is twice that of women without such medical conditions (9, 26). If feasible, oral contraceptives should be discontinued at least four weeks prior to and for two weeks after elective surgery of a type associated with an increase in risk of <span class="product-label-link" type="condition" conceptid="4159647" conceptname="Thromboembolic disorder">thromboembolism</span> and during and following prolonged immobilization. Since the immediate postpartum period is also associated with an increased risk of <span class="product-label-link" type="condition" conceptid="4159647" conceptname="Thromboembolic disorder">thromboembolism</span>, oral contraceptives should be started no earlier than four weeks after delivery in women who elect not to breast feed. </p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_5dd4c509-4e5a-415d-8055-50c6c1bba67b"></a><a name="section-6.1.2"></a><p></p>
<h3>b. <span class="product-label-link" type="condition" conceptid="4329847" conceptname="Myocardial infarction">Myocardial infarction</span></h3>
<p class="First">An increased risk of <span class="product-label-link" type="condition" conceptid="4329847" conceptname="Myocardial infarction">myocardial infarction</span> has been attributed to oral contraceptive use. This risk is primarily in smokers or women with other underlying risk factors for <span class="product-label-link" type="condition" conceptid="317576" conceptname="Coronary arteriosclerosis">coronary artery disease</span> such as <span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">hypertension</span>, <span class="product-label-link" type="condition" conceptid="437827" conceptname="Pure hypercholesterolemia">hypercholesterolemia</span>, <span class="product-label-link" type="condition" conceptid="433736" conceptname="Obesity">morbid obesity</span>, and <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span>. The relative risk of <span class="product-label-link" type="condition" conceptid="4329847" conceptname="Myocardial infarction">heart attack</span> for current oral contraceptive users has been estimated to be two to six (4-10). The risk is very low in women under the age of 30.</p>
<p>Smoking in combination with oral contraceptive use has been shown to contribute substantially to the incidence of <span class="product-label-link" type="condition" conceptid="4329847" conceptname="Myocardial infarction">myocardial infarction</span> in women in their mid-thirties or older with smoking accounting for the majority of excess cases (11). Mortality rates associated with circulatory disease have been shown to increase substantially in smokers, over the age of 35 and non-smokers over the age of 40 (Table III) among women who use oral contraceptives.</p>
<p><span class="Bold">TABLE III: CIRCULATORY DISEASE MORTALITY RATES PER 100,000 WOMAN-YEARS BY AGE, SMOKING STATUS, AND ORAL CONTRACEPTIVE USE</span></p>
<div class="Figure">
<a name="id6110514"></a><img alt="TABLE III: CIRCULATORY DISEASE MORTALITY RATES PER 100,000 WOMAN-YEARS BY AGE, SMOKING STATUS, AND ORAL CONTRACEPTIVE USE" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=39988aa6-8f68-40e8-9bdd-c40a3bdaad61&amp;name=644dec7a-1c0d-4161-a454-e280023f5735-02.jpg">
</div>
<p>Adapted from P.M. Layde and V. Beral, ref. #12.</p>
<p>Oral contraceptives may compound the effects of well-known risk factors, such as <span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">hypertension</span>, <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span>, <span class="product-label-link" type="condition" conceptid="432867" conceptname="Hyperlipidemia">hyperlipidemias</span>, age and <span class="product-label-link" type="condition" conceptid="433736" conceptname="Obesity">obesity</span> (13). In particular, some progestogens are known to decrease HDL <span class="product-label-link" type="condition" conceptid="4224820" conceptname="Cholesterol">cholesterol</span> and cause <span class="product-label-link" type="condition" conceptid="44808385" conceptname="Pre-diabetes">glucose intolerance</span>, while estrogens may create a state of <span class="product-label-link" type="condition" conceptid="4307509" conceptname="Hyperinsulinism">hyperinsulinism</span> (14-18). Oral contraceptives have been shown to increase blood pressure among users (see section 9 in WARNINGS). Similar effects on risk factors have been associated with an increased risk of heart disease. Oral contraceptives must be used with caution in women with cardiovascular disease risk factors. </p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_3844c14c-a265-42fa-96c7-274a9e941f15"></a><a name="section-6.1.3"></a><p></p>
<h3>c. Cerebrovascular diseases </h3>
<p class="First">Oral contraceptives have been shown to increase both the relative and attributable risks of cerebrovascular events (thrombotic and <span class="product-label-link" type="condition" conceptid="4046362" conceptname="Hemorrhagic cerebral infarction">hemorrhagic strokes</span>), although, in general, the risk is greatest among older (&gt; 35 years), hypertensive women who also smoke. <span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">Hypertension</span> was found to be a risk factor for both users and non-users, for both types of <span class="product-label-link" type="condition" conceptid="381316" conceptname="Cerebrovascular accident">strokes</span>, while smoking interacted to increase the risk for <span class="product-label-link" type="condition" conceptid="4046362" conceptname="Hemorrhagic cerebral infarction">hemorrhagic strokes</span> (27-29). </p>
<p>In a large study, the relative risk of <span class="product-label-link" type="condition" conceptid="4159140" conceptname="Thrombotic stroke">thrombotic strokes</span> has been shown to range from 3 for normotensive users to 14 for users with severe <span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">hypertension</span> (30). The relative risk of <span class="product-label-link" type="condition" conceptid="4046362" conceptname="Hemorrhagic cerebral infarction">hemorrhagic stroke</span> is reported to be 1.2 for non-smokers who used oral contraceptives, 2.6 for smokers who did not use oral contraceptives, 7.6 for smokers who used oral contraceptives, 1.8 for normotensive users and 25.7 for users with severe <span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">hypertension</span> (30). The attributable risk is also greater in older women (3). </p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_3f4cdd06-c0c0-42eb-9ad1-df1a940fdd90"></a><a name="section-6.1.4"></a><p></p>
<h3>d. Dose-related risk of vascular disease from oral contraceptives </h3>
<p class="First">A positive association has been observed between the amount of estrogen and progestogen in oral contraceptives and the risk of vascular disease (31-33). A decline in serum high-density lipoproteins (HDL) has been reported with many progestational agents (14-16). A decline in serum high-density lipoproteins has been associated with an increased incidence of <span class="product-label-link" type="condition" conceptid="4124683" conceptname="Silent myocardial ischemia">ischemic heart disease</span>. Because estrogens increase HDL <span class="product-label-link" type="condition" conceptid="4224820" conceptname="Cholesterol">cholesterol</span>, the net effect of an oral contraceptive depends on a balance achieved between doses of estrogen and progestogen and the nature and absolute amount of progestogens used in the contraceptives. The amount of both hormones should be considered in the choice of an oral contraceptive.</p>
<p>Minimizing exposure to estrogen and progestogen is in keeping with good principles of therapeutics. For any particular estrogen/progestogen combination, the dosage regimen prescribed should be one which contains the least amount of estrogen and progestogen that is compatible with a low failure rate and the needs of the individual patient. New acceptors of oral contraceptive agents should be started on preparations containing 0.035 mg or less of estrogen. </p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_be8e4775-4fb4-404c-8885-bf9bafd3216a"></a><a name="section-6.1.5"></a><p></p>
<h3>e. Persistence of risk of vascular disease </h3>
<p class="First">There are two studies which have shown persistence of risk of vascular disease for ever-users of oral contraceptives. In a study in the United States, the risk of developing <span class="product-label-link" type="condition" conceptid="4329847" conceptname="Myocardial infarction">myocardial infarction</span> after discontinuing oral contraceptives persists for at least 9 years for women 40 to 49 years old who had used oral contraceptives for five or more years, but this increased risk was not demonstrated in other age groups (8). In another study in Great Britain, the risk of developing cerebrovascular disease persisted for at least 6 years after discontinuation of oral contraceptives, although excess risk was very small (34). However, both studies were performed with oral contraceptive formulations containing 50 micrograms or more of estrogen.</p>
</div>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_4ae046ff-76e8-41be-ab82-83729baa917e"></a><a name="section-6.2"></a><p></p>
<h2>2. Estimates of mortality from contraceptive use</h2>
<p class="First">One study gathered data from a variety of sources which have estimated the mortality rate associated with different methods of contraception at different ages (Table IV). These estimates include the combined risk of <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span> associated with contraceptive methods plus the risk attributable to pregnancy in the event of method failure. Each method of contraception has its specific benefits and risks. The study concluded that with the exception of oral contraceptive users 35 and older who smoke and 40 and older who do not smoke, mortality associated with all methods of birth control is low and below that associated with childbirth.</p>
<p>The observation of a possible increase in risk of mortality with age for oral contraceptive users is based on data gathered in the 1970's - but not reported until 1983 (35). However, current clinical practice involves the use of lower estrogen formulations combined with careful consideration of risk factors.</p>
<p>Because of these changes in practice and, also, because of some limited new data which suggest that the risk of cardiovascular disease with the use of oral contraceptives may now be less than previously observed (100,101), the Fertility and Maternal Health Drugs Advisory Committee was asked to review the topic in 1989. The Committee concluded that although cardiovascular disease risks may be increased with oral contraceptive use after age 40 in healthy non-smoking women (even with the newer low-dose formulations), there are also greater potential health risks associated with pregnancy in older women and with the alternative surgical and medical procedures which may be necessary if such women do not have access to effective and acceptable means of contraception.</p>
<p>Therefore, the Committee recommended that the benefits of low-dose oral contraceptive use by healthy non-smoking women over 40 may outweigh the possible risks. Of course, older women, as all women who take oral contraceptives, should take the lowest possible dose formulation that is effective.</p>
<table>
<caption><span>TABLE IV: ANNUAL NUMBER OF BIRTH-RELATED OR METHOD-RELATED <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">DEATHS</span> ASSOCIATED WITH CONTROL OF FERTILITY PER 100,000 NON-STERILE WOMEN, BY FERTILITY CONTROL METHOD ACCORDING TO AGE </span></caption>
<col width="33%">
<col width="8%">
<col width="8%">
<col width="8%">
<col width="8%">
<col width="8%">
<col width="8%">
<tbody class="Headless">
<tr class="First">
<td class="Botrule Lrule Toprule" valign="top"><p class="First"><span class="Bold">Method of control and outcome</span></p></td>
<td class="Botrule Lrule Toprule" align="center" valign="top"><p class="First"><span class="Bold">15-19</span></p></td>
<td class="Botrule Lrule Toprule" align="center" valign="top"><p class="First"><span class="Bold">20-24</span></p></td>
<td class="Botrule Lrule Toprule" align="center" valign="top"><p class="First"><span class="Bold">25-29</span></p></td>
<td class="Botrule Lrule Toprule" align="center" valign="top"><p class="First"><span class="Bold">30-34</span></p></td>
<td class="Botrule Lrule Toprule" align="center" valign="top"><p class="First"><span class="Bold">35-39</span></p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><p class="First"><span class="Bold">40-44</span></p></td>
</tr>
<tr>
<td class="Botrule Lrule" valign="top"><p class="First">No fertility control methods<span class="Sup">1</span></p></td>
<td class="Botrule Lrule" align="center" valign="top"><p class="First">7.0</p></td>
<td class="Botrule Lrule" align="center" valign="top"><p class="First">7.4</p></td>
<td class="Botrule Lrule" align="center" valign="top"><p class="First">9.1</p></td>
<td class="Botrule Lrule" align="center" valign="top"><p class="First">14.8</p></td>
<td class="Botrule Lrule" align="center" valign="top"><p class="First">25.7</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="top"><p class="First">28.2</p></td>
</tr>
<tr>
<td class="Botrule Lrule" valign="top"><p class="First">Oral contraceptives non-smoker<span class="Sup">2</span></p></td>
<td class="Botrule Lrule" align="center" valign="top"><p class="First">0.3</p></td>
<td class="Botrule Lrule" align="center" valign="top"><p class="First">0.5</p></td>
<td class="Botrule Lrule" align="center" valign="top"><p class="First">0.9</p></td>
<td class="Botrule Lrule" align="center" valign="top"><p class="First">1.9</p></td>
<td class="Botrule Lrule" align="center" valign="top"><p class="First">13.8</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="top"><p class="First">31.6</p></td>
</tr>
<tr>
<td class="Botrule Lrule" valign="top"><p class="First">Oral contraceptives smoker<span class="Sup">2</span></p></td>
<td class="Botrule Lrule" align="center" valign="top"><p class="First">2.2</p></td>
<td class="Botrule Lrule" align="center" valign="top"><p class="First">3.4</p></td>
<td class="Botrule Lrule" align="center" valign="top"><p class="First">6.6</p></td>
<td class="Botrule Lrule" align="center" valign="top"><p class="First">13.5</p></td>
<td class="Botrule Lrule" align="center" valign="top"><p class="First">51.1</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="top"><p class="First">117.2</p></td>
</tr>
<tr>
<td class="Botrule Lrule" valign="top"><p class="First">IUD<span class="Sup">2</span></p></td>
<td class="Botrule Lrule" align="center" valign="top"><p class="First">0.8</p></td>
<td class="Botrule Lrule" align="center" valign="top"><p class="First">0.8</p></td>
<td class="Botrule Lrule" align="center" valign="top"><p class="First">1.0</p></td>
<td class="Botrule Lrule" align="center" valign="top"><p class="First">1.0</p></td>
<td class="Botrule Lrule" align="center" valign="top"><p class="First">1.4</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="top"><p class="First">1.4</p></td>
</tr>
<tr>
<td class="Botrule Lrule" valign="top"><p class="First">Condom<span class="Sup">1</span></p></td>
<td class="Botrule Lrule" align="center" valign="top"><p class="First">1.1</p></td>
<td class="Botrule Lrule" align="center" valign="top"><p class="First">1.6</p></td>
<td class="Botrule Lrule" align="center" valign="top"><p class="First">0.7</p></td>
<td class="Botrule Lrule" align="center" valign="top"><p class="First">0.2</p></td>
<td class="Botrule Lrule" align="center" valign="top"><p class="First">0.3</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="top"><p class="First">0.4</p></td>
</tr>
<tr>
<td class="Botrule Lrule" valign="top"><p class="First">Diaphragm/spermicide<span class="Sup">1</span></p></td>
<td class="Botrule Lrule" align="center" valign="top"><p class="First">1.9</p></td>
<td class="Botrule Lrule" align="center" valign="top"><p class="First">1.2</p></td>
<td class="Botrule Lrule" align="center" valign="top"><p class="First">1.2</p></td>
<td class="Botrule Lrule" align="center" valign="top"><p class="First">1.3</p></td>
<td class="Botrule Lrule" align="center" valign="top"><p class="First">2.2</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="top"><p class="First">2.8</p></td>
</tr>
<tr class="Last">
<td class="Botrule Lrule" valign="top"><p class="First">Periodic abstinence<span class="Sup">1</span></p></td>
<td class="Botrule Lrule" align="center" valign="top"><p class="First">2.5</p></td>
<td class="Botrule Lrule" align="center" valign="top"><p class="First">1.6</p></td>
<td class="Botrule Lrule" align="center" valign="top"><p class="First">1.6</p></td>
<td class="Botrule Lrule" align="center" valign="top"><p class="First">1.7</p></td>
<td class="Botrule Lrule" align="center" valign="top"><p class="First">2.9</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="top"><p class="First">3.6</p></td>
</tr>
</tbody>
</table>
<p><span class="Sup">1</span> <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">Deaths</span> are birth related</p>
<p><span class="Sup">2</span> <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">Deaths</span> are method related</p>
<p>Adapted from H.W. Ory, ref. #35.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_12079831-cc16-42e1-89f9-26cfe621adc1"></a><a name="section-6.3"></a><p></p>
<h2>3. Carcinoma of the reproductive organs and breasts</h2>
<p class="First">Numerous epidemiologic studies have been performed on the incidence of breast, endometrial, ovarian, and cervical cancer in women using oral contraceptives. While there are conflicting reports, most studies suggest that the use of oral contraceptives is not associated with an overall increase in the risk of developing breast cancer. Some studies have reported an increased relative risk of developing breast cancer, particularly at a younger age. This increased relative risk appears to be related to duration of use (36-43, 79-89).</p>
<p>Some studies suggest that oral contraceptive use has been associated with an increase in the risk of cervical intra-epithelial neoplasia in some populations of women (45-48). However, there continues to be controversy about the extent to which such findings may be due to differences in sexual behavior and other factors.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_f3e4583b-0c21-43bd-8c56-12dd5a3ef1e1"></a><a name="section-6.4"></a><p></p>
<h2>4. <span class="product-label-link" type="condition" conceptid="4322895" conceptname="Nodule of liver">Hepatic neoplasia</span></h2>
<p class="First">Benign <span class="product-label-link" type="condition" conceptid="4301500" conceptname="Liver cell adenoma">hepatic adenomas</span> are associated with oral contraceptive use, although the incidence of benign tumors is rare in the United States. Indirect calculations have estimated the attributable risk to be in the range of 3.3 cases/100,000 for users, a risk that increases after four or more years of use especially with oral contraceptives of higher dose (49). Rupture of rare, benign, <span class="product-label-link" type="condition" conceptid="4301500" conceptname="Liver cell adenoma">hepatic adenomas</span> may cause <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span> through intra-abdominal <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">hemorrhage</span> (50, 51).</p>
<p>Studies from Britain have shown an increased risk of developing hepatocellular carcinoma (52-54) in long-term (&gt; 8 years) oral contraceptive users. However, these cancers are extremely rare in the US and the attributable risk (the excess incidence) of liver cancers in oral contraceptive users approaches less than one per million users.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_defbe27f-d257-47a3-979a-81ee97e16902"></a><a name="section-6.5"></a><p></p>
<h2>5. Ocular lesions</h2>
<p class="First">There have been clinical case reports of retinal <span class="product-label-link" type="condition" conceptid="4130722" conceptname="Thrombosis">thrombosis</span> associated with the use of oral contraceptives. Oral contraceptives should be discontinued if there is unexplained partial or complete <span class="product-label-link" type="condition" conceptid="377551" conceptname="Blind hypertensive eye">loss of vision</span>; onset of <span class="product-label-link" type="condition" conceptid="436700" conceptname="Exophthalmos">proptosis</span> or <span class="product-label-link" type="condition" conceptid="373474" conceptname="Diplopia">diplopia</span>; <span class="product-label-link" type="condition" conceptid="4308632" conceptname="Optic disc edema">papilledema</span>; or retinal vascular lesions. Appropriate diagnostic and therapeutic measures should be undertaken immediately.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_13f7e3cd-c845-4e0e-8813-d304d4c29521"></a><a name="section-6.6"></a><p></p>
<h2>6. Oral contraceptive use before or during early pregnancy</h2>
<p class="First">Extensive epidemiologic studies have revealed no increased risk of <span class="product-label-link" type="condition" conceptid="4029540" conceptname="Congenital anomaly">birth defects</span> in women who have used oral contraceptives prior to pregnancy (55-57). Studies also do not suggest a teratogenic effect, particularly in so far as cardiac anomalies and <span class="product-label-link" type="condition" conceptid="73307" conceptname="Transverse deficiency of lower limb">limb reduction defects</span> are concerned (55,56,58,59), when oral contraceptives are taken inadvertently during early pregnancy.</p>
<p>The administration of oral contraceptives to induce <span class="product-label-link" type="condition" conceptid="4161407" conceptname="Withdrawal bleeding">withdrawal bleeding</span> should not be used as a test for pregnancy. Oral contraceptives should not be used during pregnancy to treat threatened or habitual abortion. It is recommended that for any patient who has missed two consecutive periods, pregnancy should be ruled out before continuing oral contraceptive use. If the patient has not adhered to the prescribed schedule, the possibility of pregnancy should be considered at the first missed period. Oral contraceptive use should be discontinued until pregnancy is ruled out.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_157103c4-30d6-443e-832f-561485e9eb5e"></a><a name="section-6.7"></a><p></p>
<h2>7. <span class="product-label-link" type="condition" conceptid="192353" conceptname="Disorder of gallbladder">Gallbladder disease</span></h2>
<p class="First">Earlier studies have reported an increased lifetime relative risk of gallbladder surgery in users of oral contraceptives and estrogens (60, 61). More recent studies, however, have shown that the relative risk of developing <span class="product-label-link" type="condition" conceptid="192353" conceptname="Disorder of gallbladder">gallbladder disease</span> among oral contraceptive users may be minimal (62-64). The recent findings of minimal risk may be related to the use of oral contraceptive formulations containing lower hormonal doses of estrogens and progestogens.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_3b6e3168-5300-4374-bcf2-48b3d1971a63"></a><a name="section-6.8"></a><p></p>
<h2>8. Carbohydrate and lipid metabolic effects</h2>
<p class="First">Oral contraceptives have been shown to cause a decrease in glucose tolerance in a significant percentage of users (17). Oral contraceptives containing greater than 75 micrograms of estrogens cause hyper-insulinism, while lower doses of estrogen cause less <span class="product-label-link" type="condition" conceptid="44808385" conceptname="Pre-diabetes">glucose intolerance</span> (65). Progestogens increase insulin secretion and create <span class="product-label-link" type="condition" conceptid="4168924" conceptname="Drug resistance to insulin">insulin resistance</span>, this effect varying with different progestational agents (17, 66). However, in the non-diabetic woman, oral contraceptives appear to have no effect on fasting blood glucose (67). Because of these demonstrated effects, prediabetic and diabetic women should be carefully monitored while taking oral contraceptives.</p>
<p>A small proportion of women will have persistent <span class="product-label-link" type="condition" conceptid="440360" conceptname="Pure hyperglyceridemia">hypertriglyceridemia</span> while on the pill. As discussed earlier (see <span class="Bold">WARNINGS </span><a href="#ID_3936b0e1-ab6a-4c42-a993-bf5f52e5722a">1.a.</a> and <span class="Bold"><a href="#ID_3f4cdd06-c0c0-42eb-9ad1-df1a940fdd90">1.d.</a></span>), changes in serum triglycerides and lipoprotein levels have been reported in oral contraceptive users.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_b794bf20-7323-4f7d-b81d-3facc70d2da9"></a><a name="section-6.9"></a><p></p>
<h2>9. Elevated blood pressure</h2>
<p class="First">An increase in blood pressure has been reported in women taking oral contraceptives (68) and this increase is more likely in older oral contraceptive users (69) and with continued use (61). Data from the Royal College of General Practitioners (12) and subsequent randomized trials have shown that the incidence of <span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">hypertension</span> increases with increasing quantities of progestogens.</p>
<p>Women with a history of <span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">hypertension</span> or <span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">hypertension</span>-related diseases, or <span class="product-label-link" type="condition" conceptid="198124" conceptname="Kidney disease">renal disease</span> (70) should be encouraged to use another method of contraception. If women elect to use oral contraceptives, they should be monitored closely and if significant elevation of blood pressure occurs, oral contraceptives should be discontinued. For most women, elevated blood pressure will return to normal after stopping oral contraceptives (69), and there is no difference in the occurrence of <span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">hypertension</span> between ever- and never-users (68,70,71).</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_c76ff2aa-67df-4d19-a5cb-e7cf4636569f"></a><a name="section-6.10"></a><p></p>
<h2>10. <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">Headache</span></h2>
<p class="First">The onset or exacerbation of <span class="product-label-link" type="condition" conceptid="318736" conceptname="Migraine">migraine</span> or development of <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span> with a new pattern which is recurrent, persistent, or severe requires discontinuation of oral contraceptives and evaluation of the cause.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_9f299ecf-91b2-46d3-87a5-08ec880b48b7"></a><a name="section-6.11"></a><p></p>
<h2>11. <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">Bleeding</span> irregularities</h2>
<p class="First">Breakthrough <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> and spotting are sometimes encountered in patients on oral contraceptives, especially during the first three months of use. Non-hormonal causes should be considered and adequate diagnostic measures taken to rule out malignancy or pregnancy in the event of breakthrough <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span>, as in the case of any abnormal <span class="product-label-link" type="condition" conceptid="4129155" conceptname="Vaginal bleeding">vaginal bleeding</span>. If pathology has been excluded, time or a change to another formulation may solve the problem. In the event of <span class="product-label-link" type="condition" conceptid="443800" conceptname="Amenorrhea">amenorrhea</span>, pregnancy should be ruled out.</p>
<p>Some women may encounter post-pill <span class="product-label-link" type="condition" conceptid="443800" conceptname="Amenorrhea">amenorrhea</span> or <span class="product-label-link" type="condition" conceptid="442274" conceptname="Oligomenorrhea">oligomenorrhea</span>, especially when such a condition was pre-existent.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_898f2c0b-52c0-490e-9cf5-a1035a08fe88"></a><a name="section-6.12"></a><p></p>
<h2>12. <span class="product-label-link" type="condition" conceptid="437611" conceptname="Ectopic pregnancy">Ectopic pregnancy</span></h2>
<p class="First">Ectopic as well as intrauterine pregnancy may occur in contraceptive failures.</p>
</div>
</div>
<div class="Section" data-sectionCode="42232-9">
<a name="i4i_precautions_id_bc3885a3-3935-4a6f-b3b3-7a691dd216b3"></a><a name="section-7"></a><p></p>
<h1>PRECAUTIONS</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_f7cef986-f3fe-4c07-9f86-82a1799df829"></a><a name="section-7.1"></a><p></p>
<h2>1. General</h2>
<p class="First"><span class="Bold">Patients should be counseled that this product does not protect against <span class="product-label-link" type="condition" conceptid="439727" conceptname="Human immunodeficiency virus infection">HIV infection</span> (AIDS) and other <span class="product-label-link" type="condition" conceptid="440647" conceptname="Sexually transmitted infectious disease">sexually transmitted diseases</span>.</span></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_bdba35f8-8503-4b0b-af2c-da0ac4d97a2d"></a><a name="section-7.2"></a><p></p>
<h2>2. Physical examination and follow up</h2>
<p class="First">It is good medical practice for all women to have annual history and physical examinations, including women using oral contraceptives. The physical examination, however, may be deferred until after initiation of oral contraceptives if requested by the woman and judged appropriate by the clinician. The physical examination should include special reference to blood pressure, breasts, abdomen, and pelvic organs, including cervical <span class="product-label-link" type="condition" conceptid="45771295" conceptname="Cytology">cytology</span>, and relevant laboratory tests. In case of undiagnosed, persistent or recurrent abnormal <span class="product-label-link" type="condition" conceptid="4129155" conceptname="Vaginal bleeding">vaginal bleeding</span>, appropriate measures should be conducted to rule out malignancy. Women with a strong family history of breast cancer or who have breast <span class="product-label-link" type="condition" conceptid="4101098" conceptname="Nodule">nodules</span> should be monitored with particular care.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_59ff502c-23b2-4484-88f7-adb17e8a4f3f"></a><a name="section-7.3"></a><p></p>
<h2>3. Lipid disorders</h2>
<p class="First">Women who are being treated for <span class="product-label-link" type="condition" conceptid="432867" conceptname="Hyperlipidemia">hyperlipidemias</span> should be followed closely if they elect to use oral contraceptives. Some progestogens may elevate LDL levels and may render the control of <span class="product-label-link" type="condition" conceptid="432867" conceptname="Hyperlipidemia">hyperlipidemias</span> more difficult.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_18a07350-dfa0-4057-ab00-16cbc20d5ff9"></a><a name="section-7.4"></a><p></p>
<h2>4. Liver function</h2>
<p class="First">If <span class="product-label-link" type="condition" conceptid="137977" conceptname="Jaundice">jaundice</span> develops in any woman receiving such drugs, the medication should be discontinued. Steroid hormones may be poorly metabolized in patients with <span class="product-label-link" type="condition" conceptid="4326594" conceptname="Abnormal liver function">impaired liver function</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_68947a13-d151-49b6-8e59-ba34c71c2b6d"></a><a name="section-7.5"></a><p></p>
<h2>5. <span class="product-label-link" type="condition" conceptid="4125002" conceptname="Idiopathic fluid retention">Fluid retention</span></h2>
<p class="First">Oral contraceptives may cause some degree of <span class="product-label-link" type="condition" conceptid="4125002" conceptname="Idiopathic fluid retention">fluid retention</span>. They should be prescribed with caution, and only with careful monitoring, in patients with conditions which might be aggravated by <span class="product-label-link" type="condition" conceptid="4125002" conceptname="Idiopathic fluid retention">fluid retention</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_737fcc4b-bb7c-411a-b57e-048af0a6c533"></a><a name="section-7.6"></a><p></p>
<h2>6. <span class="product-label-link" type="condition" conceptid="4305081" conceptname="Emotional problems">Emotional disorders</span></h2>
<p class="First">Women with a history of <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depression</span> should be carefully observed and the drug discontinued if <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depression</span> recurs to a serious degree.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_75e18ae9-f0a3-4c29-a3a6-080a47ebad7d"></a><a name="section-7.7"></a><p></p>
<h2>7. Contact lenses</h2>
<p class="First">Contact lens wearers who develop visual changes or changes in lens tolerance should be assessed by an ophthalmologist.</p>
</div>
<div class="Section" data-sectionCode="34073-7">
<a name="i4i_drug_interaction_id_78951b2c-4ab0-4b6b-861d-4d8d9eebb181"></a><a name="section-7.8"></a><p></p>
<h2>8. Drug interactions</h2>
<p class="First">Reduced efficacy and increased incidence of breakthrough <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> and menstrual irregularities have been associated with concomitant use of rifampin. A similar association, though less marked, has been suggested with barbiturates, phenylbutazone, phenytoin sodium, carbamazepine and possibly with griseofulvin, ampicillin, and tetracyclines (72).</p>
<p>Combined hormonal contraceptives have been shown to significantly decrease plasma concentrations of lamotrigine when co-administered, likely due to induction of lamotrigine glucuronidation. This may reduce <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizure</span> control; therefore, dosage adjustments of lamotrigine may be necessary. </p>
<p>Consult the labeling of the concurrently-used drug to obtain further information about interactions with hormonal contraceptives or the potential for enzyme alterations.</p>
</div>
<div class="Section" data-sectionCode="34074-5">
<a name="i4i_drug_lab_interaction_id_763b61cc-cdd7-4d84-81d1-a8b4b1566847"></a><a name="section-7.9"></a><p></p>
<h2>9. Interactions with laboratory tests</h2>
<p class="First">Certain endocrine and liver function tests and blood components may be affected by oral contraceptives: </p>
<dl>
<dt>1.</dt>
<dd>Increased <span class="product-label-link" type="condition" conceptid="4173906" conceptname="Clotting factor II assay">prothrombin</span> and factors VII, VIII, IX and X; decreased antithrombin 3; increased norepinephrine-induced platelet aggregability. </dd>
<dt>2.</dt>
<dd>Increased <span class="product-label-link" type="condition" conceptid="4188578" conceptname="Thyroxine binding globulin">thyroid binding globulin</span> (TBG) leading to increased circulating total thyroid hormone, as measured by protein-bound iodine (PBI), T4 by column or by radioimmunoassay. Free T3 resin uptake is decreased, reflecting the elevated TBG; free T4 concentration is unaltered. </dd>
<dt>3.</dt>
<dd>Other binding proteins may be elevated in serum. </dd>
<dt>4.</dt>
<dd>Sex hormone-binding globulins are increased and result in elevated levels of total circulating sex steroids; however, free or biologically active levels either decrease or remain unchanged. </dd>
<dt>5.</dt>
<dd>High-density lipoprotein <span class="product-label-link" type="condition" conceptid="4224820" conceptname="Cholesterol">cholesterol</span> (HDL-C) and triglycerides may be increased, while low-density lipoprotein <span class="product-label-link" type="condition" conceptid="4224820" conceptname="Cholesterol">cholesterol</span> (LDL-C) and total <span class="product-label-link" type="condition" conceptid="4224820" conceptname="Cholesterol">cholesterol</span> (Total-C) may be decreased or unchanged. </dd>
<dt>6.</dt>
<dd>Glucose tolerance may be decreased. </dd>
<dt>7.</dt>
<dd>Serum folate levels may be depressed by oral contraceptive therapy. This may be of clinical significance if a woman becomes pregnant shortly after discontinuing oral contraceptives. </dd>
</dl>
</div>
<div class="Section" data-sectionCode="34083-6">
<a name="i4i_carcinogenesis_mutagenesis_fertility_id_180142da-e164-4093-a1c0-e10787403bbf"></a><a name="section-7.10"></a><p></p>
<h2>10. Carcinogenesis</h2>
<p class="First">See <span class="Bold"><a href="#i4i_warnings_id_7dbb18ea-1b8a-4416-832f-5ac89bec8803">WARNINGS</a></span> section.</p>
</div>
<div class="Section" data-sectionCode="42228-7">
<a name="i4i_pregnancy_id_e56758ee-23a6-4a92-bb00-a7c3ac6fc7cc"></a><a name="section-7.11"></a><p></p>
<h2>11. Pregnancy</h2>
<p class="First">Pregnancy Category X (see <span class="Bold"><a href="#i4i_contraindications_id_2d774397-6f9a-4784-9005-be77b7881ccf">CONTRAINDICATIONS</a></span> and <span class="Bold"><a href="#i4i_warnings_id_7dbb18ea-1b8a-4416-832f-5ac89bec8803">WARNINGS</a></span> sections).</p>
</div>
<div class="Section" data-sectionCode="34080-2">
<a name="i4i_nursing_mothers_id_d6190440-b0ad-4646-a288-30bc2d1c89e4"></a><a name="section-7.12"></a><p></p>
<h2>12. Nursing mothers</h2>
<p class="First">Small amounts of oral contraceptive steroids have been identified in the milk of nursing mothers and a few adverse effects on the child have been reported, including <span class="product-label-link" type="condition" conceptid="137977" conceptname="Jaundice">jaundice</span> and <span class="product-label-link" type="condition" conceptid="78474" conceptname="Hypertrophy of breast">breast enlargement</span>. In addition, oral contraceptives given in the postpartum period may interfere with lactation by decreasing the quantity and quality of breast milk. If possible, the nursing mother should be advised not to use oral contraceptives but to use other forms of contraception until she has completely weaned her child.</p>
</div>
<div class="Section" data-sectionCode="34081-0">
<a name="i4i_pediatric_use_id_7f697837-db61-45b4-9eb0-fc7ea8b599c0"></a><a name="section-7.13"></a><p></p>
<h2>13. Pediatric use</h2>
<p class="First">Safety and efficacy of VIORELE has been established in women of reproductive age. Safety and efficacy are expected to be the same for post-pubertal adolescents under the age of 16 and for users 16 years and older. Use of this product before <span class="product-label-link" type="condition" conceptid="4061459" conceptname="Menarche">menarche</span> is not indicated.</p>
</div>
<div class="Section" data-sectionCode="34076-0">
<a name="i4i_info_patients_id_ae6ce634-8a0c-403d-8f04-0efc0f69da49"></a><a name="section-7.14"></a><p></p>
<h2>INFORMATION FOR THE PATIENT </h2>
<p class="First">See Patient Labeling Printed Below</p>
</div>
</div>
<div class="Section" data-sectionCode="34084-4">
<a name="i4i_adverse_effects_id_85246b40-b212-4e86-834c-14b82487e95b"></a><a name="section-8"></a><p></p>
<h1>ADVERSE REACTIONS</h1>
<p class="First">An increased risk of the following serious adverse reactions has been associated with the use of oral contraceptives (see <span class="Bold"><a href="#i4i_warnings_id_7dbb18ea-1b8a-4416-832f-5ac89bec8803">WARNINGS</a></span> section):</p>
<dl>
<dt>•</dt>
<dd><span class="product-label-link" type="condition" conceptid="320741" conceptname="Thrombophlebitis">Thrombophlebitis</span> and <span class="product-label-link" type="condition" conceptid="444247" conceptname="Venous thrombosis">venous thrombosis</span> with or without <span class="product-label-link" type="condition" conceptid="4185607" conceptname="Embolism">embolism</span> </dd>
<dt>•</dt>
<dd>Arterial <span class="product-label-link" type="condition" conceptid="4159647" conceptname="Thromboembolic disorder">thromboembolism</span> </dd>
<dt>•</dt>
<dd><span class="product-label-link" type="condition" conceptid="440417" conceptname="Pulmonary embolism">Pulmonary embolism</span> </dd>
<dt>•</dt>
<dd><span class="product-label-link" type="condition" conceptid="4329847" conceptname="Myocardial infarction">Myocardial infarction</span> </dd>
<dt>•</dt>
<dd><span class="product-label-link" type="condition" conceptid="376713" conceptname="Cerebral hemorrhage">Cerebral hemorrhage</span> </dd>
<dt>•</dt>
<dd><span class="product-label-link" type="condition" conceptid="441874" conceptname="Cerebral thrombosis">Cerebral thrombosis</span> </dd>
<dt>•</dt>
<dd><span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">Hypertension</span> </dd>
<dt>•</dt>
<dd><span class="product-label-link" type="condition" conceptid="192353" conceptname="Disorder of gallbladder">Gallbladder disease</span> </dd>
<dt>•</dt>
<dd><span class="product-label-link" type="condition" conceptid="4301500" conceptname="Liver cell adenoma">Hepatic adenomas</span> or benign <span class="product-label-link" type="condition" conceptid="4322895" conceptname="Nodule of liver">liver tumors</span> </dd>
</dl>
<p>There is evidence of an association between the following conditions and the use of oral contraceptives:</p>
<dl>
<dt>•</dt>
<dd>Mesenteric <span class="product-label-link" type="condition" conceptid="4130722" conceptname="Thrombosis">thrombosis</span>  </dd>
<dt>•</dt>
<dd>Retinal <span class="product-label-link" type="condition" conceptid="4130722" conceptname="Thrombosis">thrombosis</span> </dd>
</dl>
<p>The following adverse reactions have been reported in patients receiving oral contraceptives and are believed to be drug-related:</p>
<dl>
<dt>•</dt>
<dd><span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">Nausea</span> </dd>
<dt>•</dt>
<dd><span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">Vomiting</span> </dd>
<dt>•</dt>
<dd><span class="product-label-link" type="condition" conceptid="4302537" conceptname="Digestive system finding">Gastrointestinal symptoms</span> (such as <span class="product-label-link" type="condition" conceptid="200219" conceptname="Abdominal pain">abdominal cramps</span> and <span class="product-label-link" type="condition" conceptid="442597" conceptname="Swollen abdomen">bloating</span>) </dd>
<dt>•</dt>
<dd>Breakthrough <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> </dd>
<dt>•</dt>
<dd>Spotting </dd>
<dt>•</dt>
<dd>Change in menstrual flow </dd>
<dt>•</dt>
<dd><span class="product-label-link" type="condition" conceptid="443800" conceptname="Amenorrhea">Amenorrhea</span> </dd>
<dt>•</dt>
<dd>Temporary <span class="product-label-link" type="condition" conceptid="4035976" conceptname="Sterility">infertility</span> after discontinuation of treatment </dd>
<dt>•</dt>
<dd><span class="product-label-link" type="condition" conceptid="433595" conceptname="Edema">Edema</span> </dd>
<dt>•</dt>
<dd><span class="product-label-link" type="condition" conceptid="4264234" conceptname="Chloasma">Melasma</span> which may persist </dd>
<dt>•</dt>
<dd>Breast changes: <span class="product-label-link" type="condition" conceptid="4082445" conceptname="Tenderness">tenderness</span>, enlargement, secretion</dd>
<dt>•</dt>
<dd>Change in weight (increase or decrease) </dd>
<dt>•</dt>
<dd>Change in cervical erosion and secretion </dd>
<dt>•</dt>
<dd>Diminution in lactation when given immediately postpartum </dd>
<dt>•</dt>
<dd><span class="product-label-link" type="condition" conceptid="4185719" conceptname="Cholestatic jaundice syndrome">Cholestatic jaundice</span> </dd>
<dt>•</dt>
<dd><span class="product-label-link" type="condition" conceptid="318736" conceptname="Migraine">Migraine</span> </dd>
<dt>•</dt>
<dd><span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">Rash</span> (allergic) </dd>
<dt>•</dt>
<dd>Mental <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depression</span> </dd>
<dt>•</dt>
<dd>Reduced tolerance to carbohydrates </dd>
<dt>•</dt>
<dd><span class="product-label-link" type="condition" conceptid="198363" conceptname="Candidiasis of vagina">Vaginal candidiasis</span> </dd>
<dt>•</dt>
<dd>Change in corneal curvature (steepening) </dd>
<dt>•</dt>
<dd>Intolerance to contact lenses </dd>
</dl>
<p>The following adverse reactions have been reported in users of oral contraceptives and the association has been neither confirmed nor refuted:</p>
<dl>
<dt>•</dt>
<dd>Pre-menstrual syndrome </dd>
<dt>•</dt>
<dd><span class="product-label-link" type="condition" conceptid="375545" conceptname="Cataract">Cataracts</span> </dd>
<dt>•</dt>
<dd>Changes in appetite </dd>
<dt>•</dt>
<dd><span class="product-label-link" type="condition" conceptid="195588" conceptname="Cystitis">Cystitis</span>-like syndrome </dd>
<dt>•</dt>
<dd><span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">Headache</span> </dd>
<dt>•</dt>
<dd><span class="product-label-link" type="condition" conceptid="436817" conceptname="Feeling nervous">Nervousness</span> </dd>
<dt>•</dt>
<dd><span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">Dizziness</span> </dd>
<dt>•</dt>
<dd><span class="product-label-link" type="condition" conceptid="134718" conceptname="Hirsutism">Hirsutism</span> </dd>
<dt>•</dt>
<dd>Loss of scalp hair </dd>
<dt>•</dt>
<dd><span class="product-label-link" type="condition" conceptid="132702" conceptname="Erythema multiforme">Erythema multiforme</span> </dd>
<dt>•</dt>
<dd><span class="product-label-link" type="condition" conceptid="140176" conceptname="Erythema nodosum">Erythema nodosum</span> </dd>
<dt>•</dt>
<dd>Hemorrhagic <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">eruption</span> </dd>
<dt>•</dt>
<dd><span class="product-label-link" type="condition" conceptid="4081648" conceptname="Acute vaginitis">Vaginitis</span> </dd>
<dt>•</dt>
<dd><span class="product-label-link" type="condition" conceptid="4305376" conceptname="Porphyria">Porphyria</span> </dd>
<dt>•</dt>
<dd><span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">Impaired renal function</span> </dd>
<dt>•</dt>
<dd><span class="product-label-link" type="condition" conceptid="197253" conceptname="Hemolytic uremic syndrome">Hemolytic uremic syndrome</span> </dd>
<dt>•</dt>
<dd><span class="product-label-link" type="condition" conceptid="141095" conceptname="Acne">Acne</span> </dd>
<dt>•</dt>
<dd>Changes in libido </dd>
<dt>•</dt>
<dd><span class="product-label-link" type="condition" conceptid="4272488" conceptname="Colitis">Colitis</span> </dd>
<dt>•</dt>
<dd>Budd-Chiari Syndrome</dd>
</dl>
</div>
<div class="Section" data-sectionCode="34088-5">
<a name="i4i_overdosage_id_d3bf7a94-8435-463c-9a49-232847fcac3d"></a><a name="section-9"></a><p></p>
<h1>OVERDOSAGE</h1>
<p class="First">Serious ill effects have not been reported following acute ingestion of large doses of oral contraceptives by young children. Overdosage may cause <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>, and <span class="product-label-link" type="condition" conceptid="4161407" conceptname="Withdrawal bleeding">withdrawal bleeding</span> may occur in females.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_cd118a20-b055-4fd6-874e-5835783da9bc"></a><a name="section-10"></a><p></p>
<h1>NON-CONTRACEPTIVE HEALTH BENEFITS</h1>
<p class="First">The following non-contraceptive health benefits related to the use of oral contraceptives are supported by epidemiologic studies which largely utilized oral contraceptive formulations containing estrogen doses exceeding 0.035 mg of ethinyl estradiol or 0.05 mg of mestranol (73-78).</p>
<p>Effects on menses:</p>
<dl>
<dt>•</dt>
<dd>increased menstrual cycle regularity </dd>
<dt>•</dt>
<dd>decreased blood loss and decreased incidence of <span class="product-label-link" type="condition" conceptid="433168" conceptname="Iron deficiency anemia secondary to inadequate dietary iron intake">iron deficiency anemia</span> </dd>
<dt>•</dt>
<dd>decreased incidence of <span class="product-label-link" type="condition" conceptid="194696" conceptname="Dysmenorrhea">dysmenorrhea</span> </dd>
</dl>
<p>Effects related to inhibition of ovulation:</p>
<dl>
<dt>•</dt>
<dd>decreased incidence of functional <span class="product-label-link" type="condition" conceptid="193530" conceptname="Follicular cyst of ovary">ovarian cysts</span> </dd>
<dt>•</dt>
<dd>decreased incidence of ectopic pregnancies </dd>
</dl>
<p>Effects from long-term use:</p>
<dl>
<dt>•</dt>
<dd>decreased incidence of fibroadenomas and fibrocystic disease of the breast </dd>
<dt>•</dt>
<dd>decreased incidence of acute <span class="product-label-link" type="condition" conceptid="199067" conceptname="Inflammatory disease of female pelvic organs AND/OR tissues">pelvic inflammatory disease</span> </dd>
<dt>•</dt>
<dd>decreased incidence of endometrial cancer </dd>
<dt>•</dt>
<dd>decreased incidence of ovarian cancer</dd>
</dl>
</div>
<div class="Section" data-sectionCode="34068-7">
<a name="i4i_dosage_admin_id_221b8e46-30ad-437f-a421-38fba6abf9bb"></a><a name="section-11"></a><p></p>
<h1>DOSAGE AND ADMINISTRATION</h1>
<p class="First">To achieve maximum contraceptive effectiveness, VIORELE (desogestrel and ethinyl estradiol tablets USP and ethinyl estradiol tablets USP) must be taken exactly as directed and at intervals not exceeding 24 hours. VIORELE may be initiated using either a Sunday start or a Day 1 start.</p>
<p>NOTE: Each cycle pack <span class="product-label-link" type="condition" conceptid="443720" conceptname="Blister">blister</span> card is preprinted with the days of the week, starting with Sunday, to facilitate a Sunday start regimen. Six different “day label strips? are provided with each cycle pack <span class="product-label-link" type="condition" conceptid="443720" conceptname="Blister">blister</span> card in order to accommodate a Day 1 start regimen. In this case, the patient should place the self-adhesive “day label strip? that corresponds to her starting day over the preprinted days.</p>
<p>IMPORTANT: The possibility of ovulation and conception prior to initiation of use of VIORELE should be considered.</p>
<p>The use of VIORELE for contraception may be initiated 4 weeks postpartum in women who elect not to breast feed. When the tablets are administered during the postpartum period, the increased risk of thromboembolic disease associated with the postpartum period must be considered (see <span class="Bold"><a href="#i4i_contraindications_id_2d774397-6f9a-4784-9005-be77b7881ccf">CONTRAINDICATIONS</a></span> and <span class="Bold"><a href="#i4i_warnings_id_7dbb18ea-1b8a-4416-832f-5ac89bec8803">WARNINGS</a></span> concerning thromboembolic disease. See also PRECAUTIONS for “Nursing Mothers?). </p>
<p>If the patient starts on VIORELE postpartum, and has not yet had a period, she should be instructed to use another method of contraception until a white tablet has been taken daily for 7 days.</p>
<p><span class="Bold">SUNDAY START</span></p>
<p>When initiating a Sunday start regimen, another method of contraception should be used until after the first 7 consecutive days of administration.</p>
<p>Using a Sunday start, tablets are taken daily without interruption as follows: The first white tablet should be taken on the first Sunday after menstruation begins (if menstruation begins on Sunday, the first white tablet is taken on that day). One white tablet is taken daily for 21 days, followed by 1 green (inert) tablet daily for 2 days and 1 yellow (active) tablet daily for 5 days. For all subsequent cycles, the patient then begins a new 28-tablet regimen on the next day (Sunday) after taking the last yellow tablet. [If switching from a Sunday start oral contraceptive, the first VIORELE tablet should be taken on the second Sunday after the last tablet of a 21 day regimen or should be taken on the first Sunday after the last inactive tablet of a 28 day regimen.] </p>
<p>If a patient misses 1 white tablet, she should take the missed tablet as soon as she remembers. If the patient misses 2 consecutive white tablets in Week 1 or Week 2, the patient should take 2 tablets the day she remembers and 2 tablets the next day; thereafter, the patient should resume taking 1 tablet daily until she finishes the cycle pack. The patient should be instructed to use a back-up method of birth control if she has intercourse in the 7 days after missing pills. If the patient misses 2 consecutive white tablets in the third week or misses 3 or more white tablets in a row at any time during the cycle, the patient should keep taking 1 white tablet daily until the next Sunday. On Sunday the patient should throw out the rest of that cycle pack and start a new cycle pack that same day. The patient should be instructed to use a back-up method of birth control if she has intercourse in the 7 days after missing pills.</p>
<p><span class="Bold">DAY 1 START</span></p>
<p>Counting the first day of menstruation as “Day 1?, tablets are taken without interruption as follows: One white tablet daily for 21 days, one green (inert) tablet daily for 2 days followed by 1 yellow (ethinyl estradiol) tablet daily for 5 days. For all subsequent cycles, the patient then begins a new 28-tablet regimen on the next day after taking the last yellow tablet. [If switching directly from another oral contraceptive, the first white tablet should be taken on the first day of menstruation which begins after the last ACTIVE tablet of the previous product.]</p>
<p>If a patient misses 1 white tablet, she should take the missed tablet as soon as she remembers. If the patient misses 2 consecutive white tablets in Week 1 or Week 2, the patient should take 2 tablets the day she remembers and 2 tablets the next day; thereafter, the patient should resume taking 1 tablet daily until she finishes the cycle pack. The patient should be instructed to use a back-up method of birth control if she has intercourse in the 7 days after missing pills. If the patient misses 2 consecutive white tablets in the third week or if the patient misses 3 or more white tablets in a row at any time during the cycle, the patient should throw out the rest of that cycle pack and start a new cycle pack that same day. The patient should be instructed to use a back-up method of birth control if she has intercourse in the 7 days after missing pills.</p>
<p><span class="Bold">ALL ORAL CONTRACEPTIVES</span></p>
<p>Breakthrough <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span>, spotting, and <span class="product-label-link" type="condition" conceptid="443800" conceptname="Amenorrhea">amenorrhea</span> are frequent reasons for patients discontinuing oral contraceptives. In breakthrough <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span>, as in all cases of irregular <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> from the vagina, non-functional causes should be borne in mind. In undiagnosed persistent or recurrent abnormal <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> from the vagina, adequate diagnostic measures are indicated to rule out pregnancy or malignancy. If both pregnancy and pathology have been excluded, time or a change to another preparation may solve the problem. Changing to an oral contraceptive with a higher estrogen content, while potentially useful in minimizing <span class="product-label-link" type="condition" conceptid="196168" conceptname="Irregular periods">menstrual irregularity</span>, should be done only if necessary since this may increase the risk of thromboembolic disease.</p>
<p>Use of oral contraceptives in the event of a missed menstrual period:</p>
<dl>
<dt>1.</dt>
<dd>If the patient has not adhered to the prescribed schedule, the possibility of pregnancy should be considered at the time of the first missed period and oral contraceptive use should be discontinued until pregnancy is ruled out. </dd>
<dt>2.</dt>
<dd>If the patient has adhered to the prescribed regimen and misses two consecutive periods, pregnancy should be ruled out before continuing oral contraceptive use.</dd>
</dl>
</div>
<div class="Section" data-sectionCode="34069-5">
<a name="i4i_how_supplied_id_1131aada-4f11-4085-8f5f-d491f295d0c5"></a><a name="section-12"></a><p></p>
<h1>HOW SUPPLIED</h1>
<p class="First">VIORELE (desogestrel and ethinyl estradiol tablets USP and ethinyl estradiol tablets USP) contains 21 round white tablets, 2 round green tablets and 5 round yellow tablets in a <span class="product-label-link" type="condition" conceptid="443720" conceptname="Blister">blister</span> card. Each white, biconvex, film coated tablet (debossed with ‘C1’ on one side and ‘G’ on other side) contains 0.15 mg desogestrel and 0.02 mg ethinyl estradiol USP. Each green, biconvex, film coated tablet (debossed with ‘C3’ on one side and ‘G’ on other side) contains inert ingredients. Each yellow colored, biconvex, film coated tablet (debossed with ‘C2’ on one side and ‘G’ on other side) contains 0.01 mg ethinyl estradiol USP.</p>
<p>Boxes of 3         NDC 68462-318-29</p>
<p><span class="Bold">Storage</span></p>
<p>Store at 20° to 25°C (68° to 77°F). [See USP Controlled Room Temperature].</p>
</div>
<div class="Section" data-sectionCode="34093-5">
<a name="i4i_references_id_5bbe1c10-dea9-47e6-9ff3-abeab41dcc93"></a><a name="section-13"></a><p></p>
<h1>REFERENCES</h1>
<p class="First"><span class="Bold">1.</span> Hatcher RA, Trussell J, Stewart F et al. Contraceptive Technology: Seventeenth Revised Edition, New York: Irvington Publishers, 1998, in press. </p>
<p><span class="Bold">2. </span>Stadel BV. Oral contraceptives and cardiovascular disease. (Pt. 1). N Engl J Med 1981; 305:612-618. </p>
<p><span class="Bold">3. </span>Stadel BV. Oral contraceptives and cardiovascular disease. (Pt. 2). N Engl J Med 1981; 305:672-677. </p>
<p><span class="Bold">4. </span>Adam SA, Thorogood M. Oral contraception and <span class="product-label-link" type="condition" conceptid="4329847" conceptname="Myocardial infarction">myocardial infarction</span> revisited: the effects of new preparations and prescribing patterns. Br J Obstet and Gynecol 1981; 88:838-845. </p>
<p><span class="Bold">5. </span>Mann JI, Inman WH. Oral contraceptives and <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span> from <span class="product-label-link" type="condition" conceptid="4329847" conceptname="Myocardial infarction">myocardial infarction</span>. Br Med J 1975; 2(5965):245-248. </p>
<p><span class="Bold">6. </span>Mann JI, Vessey MP, Thorogood M, Doll R. <span class="product-label-link" type="condition" conceptid="4329847" conceptname="Myocardial infarction">Myocardial infarction</span> in young women with special reference to oral contraceptive practice. Br Med J 1975; 2(5956):241-245. </p>
<p><span class="Bold">7. </span>Royal College of General Practitioners' Oral Contraception Study: Further analyses of mortality in oral contraceptive users. Lancet 1981; 1:541-546. </p>
<p><span class="Bold">8. </span>Slone D, Shapiro S, Kaufman DW, Rosenberg L, Miettinen OS, Stolley PD. Risk of <span class="product-label-link" type="condition" conceptid="4329847" conceptname="Myocardial infarction">myocardial infarction</span> in relation to current and discontinued use of oral contraceptives. N Engl J Med 1981; 305:420-424.</p>
<p><span class="Bold">9. </span>Vessey MP. Female hormones and vascular disease-an epidemiological overview. Br J Fam Plann 1980; 6:1-12. </p>
<p><span class="Bold">10. </span>Russell-Briefel RG, Ezzati TM, Fulwood R, Perlman JA, Murphy RS. Cardiovascular risk status and oral contraceptive use, United States, 1976-80. Prevent Med 1986; 15:352-362. </p>
<p><span class="Bold">11. </span>Goldbaum GM, Kendrick JS, Hogelin GC, Gentry EM. The relative impact of smoking and oral contraceptive use on women in the United States. JAMA 1987; 258:1339-1342. </p>
<p><span class="Bold">12. </span>Layde PM, Beral V. Further analyses of mortality in oral contraceptive users: Royal College General Practitioners' Oral Contraception Study. (Table 5) Lancet 1981; 1:541-546. </p>
<p><span class="Bold">13. </span>Knopp RH. <span class="product-label-link" type="condition" conceptid="4103842" conceptname="Arteriosclerosis">Arteriosclerosis</span> risk: the roles of oral contraceptives and postmenopausal estrogens. J Reprod Med 1986; 31(9) (Supplement):913-921. </p>
<p><span class="Bold">14. </span>Krauss RM, Roy S, Mishell DR, Casagrande J, Pike MC. Effects of two low-dose oral contraceptives on serum lipids and lipoproteins: Differential changes in high-density lipoproteins subclasses. Am J Obstet 1983; 145:446-452. </p>
<p><span class="Bold">15. </span>Wahl P, Walden C, Knopp R, Hoover J, Wallace R, Heiss G, Rifkind B. Effect of estrogen/progestin potency on lipid/lipoprotein <span class="product-label-link" type="condition" conceptid="4224820" conceptname="Cholesterol">cholesterol</span>. N Engl J Med 1983; 308:862-867. </p>
<p><span class="Bold">16. </span>Wynn V, Niththyananthan R. The effect of progestin in combined oral contraceptives on serum lipids with special reference to high-density lipoproteins. Am J Obstet Gynecol 1982; 142:766-771. </p>
<p><span class="Bold">17. </span>Wynn V, Godsland I. Effects of oral contraceptives and carbohydrate metabolism. J Reprod Med 1986; 31 (9) (Supplement):892-897. </p>
<p><span class="Bold">18. </span>LaRosa JC. Atherosclerotic risk factors in cardiovascular disease. J Reprod Med 1986; 31 (9) (Supplement):906-912. </p>
<p><span class="Bold">19. </span>Inman WH, Vessey MP. Investigation of <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span> from pulmonary, coronary, and <span class="product-label-link" type="condition" conceptid="441874" conceptname="Cerebral thrombosis">cerebral thrombosis</span> and <span class="product-label-link" type="condition" conceptid="4185607" conceptname="Embolism">embolism</span> in women of child-bearing age. Br Med J 1968; 2 (5599):193-199. </p>
<p><span class="Bold">20. </span>Maguire MG, Tonascia J, Sartwell PE, Stolley PD, Tockman MS. Increased risk of <span class="product-label-link" type="condition" conceptid="4130722" conceptname="Thrombosis">thrombosis</span> due to oral contraceptives: a further report. Am J Epidemiol 1979; 110 (2):188-195. </p>
<p><span class="Bold">21. </span>Pettiti DB, Wingerd J, Pellegrin F, Ramacharan S. Risk of vascular disease in women: smoking, oral contraceptives, noncontraceptive estrogens, and other factors. JAMA 1979; 242:1150-1154. </p>
<p><span class="Bold">22. </span>Vessey MP, Doll R. Investigation of relation between use of oral contraceptives and thromboembolic disease. Br Med J 1968; 2 (5599):199-205. </p>
<p><span class="Bold">23. </span>Vessey MP, Doll R. Investigation of relation between use of oral contraceptives and thromboembolic disease. A further report. Br Med J 1969; 2 (5658):651-657. </p>
<p><span class="Bold">24. </span>Porter JB, Hunter JR, Danielson DA, Jick H, Stergachis A. Oral contraceptives and non-fatal vascular disease-recent experience. Obstet Gynecol 1982; 59 (3):299-302. </p>
<p><span class="Bold">25. </span>Vessey M, Doll R, Peto R, Johnson B, Wiggins P. A long-term follow-up study of women using different methods of contraception: an interim report. Biosocial Sci 1976; 8:375-427. </p>
<p><span class="Bold">26. </span>Royal College of General Practitioners: Oral contraceptives, <span class="product-label-link" type="condition" conceptid="444247" conceptname="Venous thrombosis">venous thrombosis</span>, and <span class="product-label-link" type="condition" conceptid="312349" conceptname="Venous varices">varicose veins</span>. J Royal Coll Gen Pract 1978; 28:393-399. </p>
<p><span class="Bold">27. </span>Collaborative Group for the Study of <span class="product-label-link" type="condition" conceptid="381316" conceptname="Cerebrovascular accident">Stroke</span> in Young Women: Oral contraception and increased risk of <span class="product-label-link" type="condition" conceptid="374384" conceptname="Cerebral ischemia">cerebral ischemia</span> or <span class="product-label-link" type="condition" conceptid="4130722" conceptname="Thrombosis">thrombosis</span>. N Engl J Med 1973; 288:871-878. </p>
<p><span class="Bold">28. </span>Petitti DB, Wingerd J. Use of oral contraceptives, cigarette smoking, and risk of <span class="product-label-link" type="condition" conceptid="432923" conceptname="Subarachnoid hemorrhage">subarachnoid hemorrhage</span>. Lancet 1978; 2:234-236. </p>
<p><span class="Bold">29. </span>Inman WH. Oral contraceptives and fatal sub-arachnoid <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">hemorrhage</span>. Br Med J 1979; 2 (6203):1468-70. </p>
<p><span class="Bold">30. </span>Collaborative Group for the Study of <span class="product-label-link" type="condition" conceptid="381316" conceptname="Cerebrovascular accident">Stroke</span> in Young Women: Oral contraceptives and <span class="product-label-link" type="condition" conceptid="381316" conceptname="Cerebrovascular accident">stroke</span> in young women: associated risk factors. JAMA 1975; 231:718-722.</p>
<p><span class="Bold">31. </span>Inman WH, Vessey MP, Westerholm B, Engelund A. Thromboembolic disease and the steroidal content of oral contraceptives. A report to the Committee on Safety of Drugs. Br Med J 1970; 2:203-209. </p>
<p><span class="Bold">32. </span>Meade TW, Greenberg G, Thompson SG. Progestogens and cardiovascular reactions associated with oral contraceptives and a comparison of the safety of 50- and 35-mcg oestrogen preparations. Br Med J 1980; 280 (6224):1157-1161. </p>
<p><span class="Bold">33. </span>Kay CR. Progestogens and arterial disease-evidence from the Royal College of General Practitioners' Study. Am J Obstet Gynecol 1982; 142:762-765. </p>
<p><span class="Bold">34. </span>Royal College of General Practitioners: Incidence of arterial disease among oral contraceptive users. J Royal Coll Gen Pract 1983; 33:75-82. </p>
<p><span class="Bold">35. </span>Ory HW. Mortality associated with fertility and fertility control: 1983. Family Planning Perspectives 1983; 15:50-56. </p>
<p><span class="Bold">36. </span>The Cancer and Steroid Hormone Study of the Centers for Disease Control and the National Institute of Child Health and Human Development: Oral-contraceptive use and the risk of breast cancer. N Engl J Med 1986; 315:405-411. </p>
<p><span class="Bold">37. </span>Pike MC, Henderson BE, Krailo MD, Duke A, Roy S. Breast cancer risk in young women and use of oral contraceptives: possible modifying effect of formulation and age at use. Lancet 1983; 2:926-929. </p>
<p><span class="Bold">38. </span>Paul C, Skegg DG, Spears GFS, Kaldor JM. Oral contraceptives and breast cancer: A national study. Br Med J 1986; 293:723-725. </p>
<p><span class="Bold">39. </span>Miller DR, Rosenberg L, Kaufman DW, Schottenfeld D, Stolley PD, Shapiro S. Breast cancer risk in relation to early oral contraceptive use. Obstet Gynecol 1986; 68:863-868. </p>
<p><span class="Bold">40. </span>Olson H, Olson KL, Moller TR, Ranstam J, Holm P. Oral contraceptive use and breast cancer in young women in Sweden (letter). Lancet 1985; 2:748-749. </p>
<p><span class="Bold">41. </span>McPherson K, Vessey M, Neil A, Doll R, Jones L, Roberts M. Early contraceptive use and breast cancer: Results of another case-control study. Br J Cancer 1987; 56:653-660.</p>
<p><span class="Bold">42. </span>Huggins GR, Zucker PF. Oral contraceptives and neoplasia: 1987 update. Fertil Steril 1987; 47:733-761. </p>
<p><span class="Bold">43. </span>McPherson K, Drife JO. The pill and breast cancer: why the uncertainty? Br Med J 1986; 293:709-710. </p>
<p><span class="Bold">44. </span>Shapiro S. Oral contraceptives-time to take stock. N Engl J Med 1987; 315:450-451. </p>
<p><span class="Bold">45. </span>Ory H, Naib Z, Conger SB, Hatcher RA, Tyler CW. Contraceptive choice and prevalence of <span class="product-label-link" type="condition" conceptid="192367" conceptname="Dysplasia of cervix">cervical dysplasia</span> and carcinoma in situ. Am J Obstet Gynecol 1976; 124:573-577. </p>
<p><span class="Bold">46. </span>Vessey MP, Lawless M, McPherson K, Yeates D. Neoplasia of the cervix uteri and contraception: a possible adverse effect of the pill. Lancet 1983; 2:930. </p>
<p><span class="Bold">47. </span>Brinton LA, Huggins GR, Lehman HF, Malli K, Savitz DA, Trapido E, Rosenthal J, Hoover R. Long-term use of oral contraceptives and risk of invasive cervical cancer. Int J Cancer 1986; 38:339-344. </p>
<p><span class="Bold">48. </span>WHO Collaborative Study of Neoplasia and Steroid Contraceptives: Invasive cervical cancer and combined oral contraceptives. Br Med J 1985; 209:961-965. </p>
<p><span class="Bold">49. </span>Rooks JB, Ory HW, Ishak KG, Strauss LT, Greenspan JR, Hill AP, Tyler CW. Epidemiology of <span class="product-label-link" type="condition" conceptid="4301500" conceptname="Liver cell adenoma">hepatocellular adenoma</span>: the role of oral contraceptive use. JAMA 1979; 242:644-648. </p>
<p><span class="Bold">50. </span>Bein NN, Goldsmith HS. Recurrent massive <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">hemorrhage</span> from benign hepatic tumors secondary to oral contraceptives. Br J Surg 1977; 64:433-435. </p>
<p><span class="Bold">51. </span>Klatskin G. Hepatic tumors: possible relationship to use of oral contraceptives. Gastroenterology 1977; 73:386-394. </p>
<p><span class="Bold">52. </span>Henderson BE, Preston-Martin S, Edmondson HA, Peters RL, Pike MC. Hepatocellular carcinoma and oral contraceptives. Br J Cancer 1983; 48:437-440. </p>
<p><span class="Bold">53. </span>Neuberger J, Forman D, Doll R, Williams R. Oral contraceptives and hepatocellular carcinoma. Br Med J 1986; 292:1355-1357. </p>
<p><span class="Bold">54. </span>Forman D, Vincent TJ, Doll R. Cancer of the liver and oral contraceptives. Br Med J 1986; 292:1357-1361. </p>
<p><span class="Bold">55. </span>Harlap S, Eldor J. Births following oral contraceptive failures. Obstet Gynecol 1980; 55:447-452. </p>
<p><span class="Bold">56. </span>Savolainen E, Saksela E, Saxen L. Teratogenic hazards of oral contraceptives analyzed in a national malformation register. Am J Obstet Gynecol 1981; 140:521-524. </p>
<p><span class="Bold">57. </span>Janerich DT, Piper JM, Glebatis DM. Oral contraceptives and <span class="product-label-link" type="condition" conceptid="4029540" conceptname="Congenital anomaly">birth defects</span>. Am J Epidemiol 1980; 112:73-79. </p>
<p><span class="Bold">58. </span>Ferencz C, Matanoski GM, Wilson PD, Rubin JD, Neill CA, Gutberlet R. Maternal hormone therapy and congenital heart disease. Teratology 1980; 21:225-239. </p>
<p><span class="Bold">59. </span>Rothman KJ, Fyler DC, Goldbatt A, Kreidberg MB. Exogenous hormones and other drug exposures of children with congenital heart disease. Am J Epidemiol 1979; 109:433-439. </p>
<p><span class="Bold">60. </span>Boston Collaborative Drug Surveillance Program: Oral contraceptives and venous thromboembolic disease, surgically confirmed <span class="product-label-link" type="condition" conceptid="192353" conceptname="Disorder of gallbladder">gallbladder disease</span>, and breast tumors. Lancet 1973; 1:1399-1404. </p>
<p><span class="Bold">61. </span>Royal College of General Practitioners: Oral contraceptives and health. New York, Pittman, 1974. </p>
<p><span class="Bold">62. </span>Layde PM, Vessey MP, Yeates D. Risk of <span class="product-label-link" type="condition" conceptid="192353" conceptname="Disorder of gallbladder">gallbladder disease</span>: a cohort study of young women attending family planning clinics. J Epidemiol Community Health 1982; 36:274-278. </p>
<p><span class="Bold">63. </span>Rome Group for the Epidemiology and Prevention of <span class="product-label-link" type="condition" conceptid="4098112" conceptname="Biliary sludge">Cholelithiasis</span> (GREPCO): Prevalence of gallstone disease in an Italian adult female population. Am J Epidemiol 1984; 119:796-805. </p>
<p><span class="Bold">64. </span>Strom BL, Tamragouri RT, Morse ML, Lazar EL, West SL, Stolley PD, Jones JK. Oral contraceptives and other risk factors for <span class="product-label-link" type="condition" conceptid="192353" conceptname="Disorder of gallbladder">gallbladder disease</span>. Clin Pharmacol Ther 1986; 39:335-341. </p>
<p><span class="Bold">65. </span>Wynn V, Adams PW, Godsland IF, Melrose J, Niththyananthan R, Oakley NW, Seedj A. Comparison of effects of different combined oral-contraceptive formulations on carbohydrate and lipid metabolism. Lancet 1979; 1:1045-1049. </p>
<p><span class="Bold">66. </span>Wynn V. Effect of progesterone and progestins on carbohydrate metabolism. In Progesterone and Progestin. Edited by Bardin CW, Milgrom E, Mauvis-Jarvis P. New York, Raven Press, 1983 pp. 395-410. </p>
<p><span class="Bold">67. </span>Perlman JA, Roussell-Briefel RG, Ezzati TM, Lieberknecht G. Oral glucose tolerance and the potency of oral contraceptive progestogens. J Chronic Dis 1985; 38:857-864. </p>
<p><span class="Bold">68. </span>Royal College of General Practitioners' Oral Contraception Study: Effect on <span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">hypertension</span> and benign breast disease of progestogen component in combined oral contraceptives. Lancet 1977; 1:624. </p>
<p><span class="Bold">69. </span>Fisch IR, Frank J. Oral contraceptives and blood pressure. JAMA 1977; 237:2499-2503. </p>
<p><span class="Bold">70. </span>Laragh AJ. Oral contraceptive induced <span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">hypertension</span>-nine years later. Am J Obstet Gynecol 1976; 126:141-147. </p>
<p><span class="Bold">71. </span>Ramcharan S, Peritz E, Pellegrin FA, Williams WT. Incidence of <span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">hypertension</span> in the Walnut Creek Contraceptive Drug Study cohort. In Pharmacology of Steroid Contraceptive Drugs. Garattini S, Berendes HW. Eds. New York, Raven Press, 1977 pp. 277-288. (Monographs of the Mario Negri Institute for Pharmacological Research, Milan). </p>
<p><span class="Bold">72. </span>Stockley I. Interactions with oral contraceptives. J Pharm 1976; 216:140-143. </p>
<p><span class="Bold">73. </span>The Cancer and Steroid Hormone Study of the Centers for Disease Control and the National Institute of Child Health and Human Development: Oral contraceptive use and the risk of ovarian cancer. JAMA 1983; 249:1596-1599. </p>
<p><span class="Bold">74. </span>The Cancer and Steroid Hormone Study of the Centers for Disease Control and the National Institute of Child Health and Human Development: Combination oral contraceptive use and the risk of endometrial cancer. JAMA 1987; 257:796-800. </p>
<p><span class="Bold">75. </span>Ory HW. Functional <span class="product-label-link" type="condition" conceptid="193530" conceptname="Follicular cyst of ovary">ovarian cysts</span> and oral contraceptives: negative association confirmed surgically. JAMA 1974; 228:68-69. </p>
<p><span class="Bold">76. </span>Ory HW, Cole P, Macmahon B, Hoover R. Oral contraceptives and reduced risk of benign breast disease. N Engl J Med 1976; 294:419-422. </p>
<p><span class="Bold">77. </span>Ory HW. The noncontraceptive health benefits from oral contraceptive use. Fam Plann Perspect 1982; 14:182-184. </p>
<p><span class="Bold">78. </span>Ory HW, Forrest JD, Lincoln R. Making Choices: Evaluating the health risks and benefits of birth control methods. New York, The Alan Guttmacher Institute, 1983; p. 1. </p>
<p><span class="Bold">79. </span>Schlesselman J, Stadel BV, Murray P, Lai S. Breast Cancer in relation to early use of oral contraceptives 1988; 259:1828-1833. </p>
<p><span class="Bold">80. </span>Hennekens CH, Speizer FE, Lipnick RJ, Rosner B, Bain C, Belanger C, Stampfer MJ, Willett W, Peto R. A case-controlled study of oral contraceptive use and breast cancer. JNCI 1984; 72:39-42. </p>
<p><span class="Bold">81. </span>LaVecchia C, Decarli A, Fasoli M, Franceschi S, Gentile A, Negri E, Parazzini F, Tognoni G. Oral contraceptives and cancers of the breast and of the female genital tract. Interim results from a case-control study. Br. J. Cancer 1986; 54:311-317. </p>
<p><span class="Bold">82. </span>Meirik O, Lund E, Adami H, Bergstrom R, Christoffersen T, Bergsjo P. Oral contraceptive use in breast cancer in young women. A Joint National Case-control study in Sweden and Norway. Lancet 1986; 11:650-654. </p>
<p><span class="Bold">83. </span>Kay CR, Hannaford PC. Breast cancer and the pill-A further report from the Royal College of General Practitioners' oral contraception study. Br. J. Cancer 1988; 58:675-680.</p>
<p><span class="Bold">84. </span>Stadel BV, Lai S, Schlesselman JJ, Murray P. Oral contraceptives and premenopausal breast cancer in nulliparous women. Contraception 1988; 38:287-299. </p>
<p><span class="Bold">85. </span>Miller DR, Rosenberg L, Kaufman DW, Stolley P, Warshauer ME, Shapiro S. Breast cancer before age 45 and oral contraceptive use: New Findings. Am. J. Epidemiol 1989; 129:269-280. </p>
<p><span class="Bold">86. </span>The UK National Case-Control Study Group, Oral contraceptive use and breast cancer risk in young women. Lancet 1989; 1:973-982. </p>
<p><span class="Bold">87. </span>Schlesselman JJ. Cancer of the breast and reproductive tract in relation to use of oral contraceptives. Contraception 1989; 40:1-38. </p>
<p><span class="Bold">88. </span>Vessey MP, McPherson K, Villard-Mackintosh L, Yeates D. Oral contraceptives and breast cancer: latest findings in a large cohort study. Br. J. Cancer 1989; 59:613-617.</p>
<p><span class="Bold">89. </span>Jick SS, Walker AM, Stergachis A, Jick H. Oral contraceptives and breast cancer. Br. J. Cancer 1989; 59:618-621. </p>
<p><span class="Bold">90. </span>Godsland, I et al. The effects of different formulations of oral contraceptive agents on lipid and carbohydrate metabolism. N Engl J Med 1990; 323:1375-81. </p>
<p><span class="Bold">91. </span>Kloosterboer, HJ et al. Selectivity in progesterone and androgen receptor binding of progestogens used in oral contraception. Contraception, 1988; 38:325-32. </p>
<p><span class="Bold">92. </span>Van der Vies, J and de Visser, J. Endocrinological studies with desogestrel. Arzneim. Forsch./Drug Res., 1983; 33(l),2:231-6. </p>
<p><span class="Bold">93. </span>Data on file, Organon Inc. </p>
<p><span class="Bold">94. </span>Fotherby, K. Oral contraceptives, lipids and cardiovascular diseases. Contraception, 1985; Vol. 31; 4:367-94. </p>
<p><span class="Bold">95. </span>Lawrence, DM et al. Reduced <span class="product-label-link" type="condition" conceptid="4206320" conceptname="Sex steroid binding globulin">sex hormone binding globulin</span> and derived free testosterone levels in women with severe <span class="product-label-link" type="condition" conceptid="141095" conceptname="Acne">acne</span>. Clinical Endocrinology, 1981; 15:87-91. </p>
<p><span class="Bold">96. </span>Cullberg, G et al. Effects of a low-dose desogestrel-ethinyl estradiol combination on <span class="product-label-link" type="condition" conceptid="134718" conceptname="Hirsutism">hirsutism</span>, <span class="product-label-link" type="condition" conceptid="4233066" conceptname="Androgen level">androgens</span> and <span class="product-label-link" type="condition" conceptid="4206320" conceptname="Sex steroid binding globulin">sex hormone binding globulin</span> in women with a <span class="product-label-link" type="condition" conceptid="195501" conceptname="Polycystic ovaries">polycystic ovary</span> syndrome. Acta Obstet Gynecol Scand, 1985; 64:195-202.</p>
<p><span class="Bold">97. </span>Jung-Hoffmann, C and Kuhl, H. Divergent effects of two low-dose oral contraceptives on sex hormone-binding globulin and free testosterone. AJOG, 1987; 156:199-203. </p>
<p><span class="Bold">98. </span>Hammond, G et al. Serum steroid binding protein concentrations, distribution of progestogens, and bioavailability of testosterone during treatment with contraceptives containing desogestrel or levonorgestrel. Fertil. Steril., 1984; 42:44-51.</p>
<p><span class="Bold">99. </span>Palatsi, R et al. Serum total and unbound testosterone and <span class="product-label-link" type="condition" conceptid="4206320" conceptname="Sex steroid binding globulin">sex hormone binding globulin</span> (SHBG) in female <span class="product-label-link" type="condition" conceptid="141095" conceptname="Acne">acne</span> patients treated with two different oral contraceptives. Acta Derm Venereol, 1984; 64:517-23. </p>
<p><span class="Bold">100. </span>Porter JB, Hunter J, Jick H et al. Oral contraceptives and nonfatal vascular disease. Obstet Gynecol 1985; 66:1-4. </p>
<p><span class="Bold">101. </span>Porter JB, Jick H, Walker AM. Mortality among oral contraceptive users. Obstet Gynecol 1987; 7029-32. </p>
<p><span class="Bold">102. </span>Jick H, Jick SS, Gurewich V, Myers MW, Vasilakis C. Risk of idiopathic cardiovascular <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span> and non-fatal <span class="product-label-link" type="condition" conceptid="318775" conceptname="Venous embolism">venous thromboembolism</span> in women using oral contraceptives with differing progestagen components. Lancet, 1995; 346:1589-93. </p>
<p><span class="Bold">103. </span>World Health Organization Collaborative Study of Cardiovascular Disease and Steroid Hormone Contraception. Effect of different progestagens in low oestrogen oral contraceptives on venous thromboembolic disease. Lancet, 1995; 346:1582-88. </p>
<p><span class="Bold">104. </span>Spitzer WO, Lewis MA, Heinemann LAJ, Thorogood M, MacRae KD on behalf of Transnational Research Group on Oral Contraceptives and Health of Young Women. Third generation oral contraceptives and risk of venous thromboembolic disorders: An international case-control study. Br Med J, 1996; 312:83-88.</p>
<p><span class="Bold">105</span>. Christensen J, Petrenaite V, Atterman J, et al. Oral contraceptives induce lamotrigine metabolism: evidence from a doubleblind,placebo-controlled trial. Epilepsia 2007;48(3):484-489.</p>
</div>
<div class="Section" data-sectionCode="42230-3">
<a name="i4i_patient_package_insert_id_a3a13198-2f33-4d58-8587-f79c82997e88"></a><a name="section-14"></a><p></p>
<h1>PATIENT PACKAGE INSERT<br>BRIEF SUMMARY</h1>
<p class="First"><span class="Bold">VIORELE (Desogestrel and Ethinyl Estradiol Tablets USP, 0.15 mg/0.02 mg and Ethinyl Estradiol Tablets USP, 0.01 mg)</span></p>
<p><span class="Bold">This product (like all oral contraceptives) is intended to prevent pregnancy. It does not protect against <span class="product-label-link" type="condition" conceptid="439727" conceptname="Human immunodeficiency virus infection">HIV infection</span> (AIDS) and other <span class="product-label-link" type="condition" conceptid="440647" conceptname="Sexually transmitted infectious disease">sexually transmitted diseases</span>.</span></p>
<p>Oral contraceptives, also known as “birth control pills? or “the pill?, are taken to prevent pregnancy, and when taken correctly, have a failure rate of about 1% per year when used without missing any pills. The typical failure rate of large numbers of pill users is less than 5% per year when women who miss pills are included. For most women, oral contraceptives are also free of serious or unpleasant side effects. However, forgetting to take pills considerably increases the chances of pregnancy.</p>
<p>For the majority of women, oral contraceptives can be taken safely. But there are some women who are at high risk of developing certain serious diseases that can be life-threatening or may cause temporary or permanent <span class="product-label-link" type="condition" conceptid="4052648" conceptname="Disability">disability</span>. The risks associated with taking oral contraceptives increase significantly if you: </p>
<dl>
<dt>•</dt>
<dd>smoke </dd>
<dt>•</dt>
<dd>have high blood pressure, <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span>, high <span class="product-label-link" type="condition" conceptid="4224820" conceptname="Cholesterol">cholesterol</span> </dd>
<dt>•</dt>
<dd>have or have had <span class="product-label-link" type="condition" conceptid="432585" conceptname="Blood coagulation disorder">clotting disorders</span>, <span class="product-label-link" type="condition" conceptid="4329847" conceptname="Myocardial infarction">heart attack</span>, <span class="product-label-link" type="condition" conceptid="381316" conceptname="Cerebrovascular accident">stroke</span>, <span class="product-label-link" type="condition" conceptid="321318" conceptname="Angina pectoris">angina pectoris</span>, cancer of the breast or sex organs, <span class="product-label-link" type="condition" conceptid="137977" conceptname="Jaundice">jaundice</span>, or malignant or benign <span class="product-label-link" type="condition" conceptid="4322895" conceptname="Nodule of liver">liver tumors</span>. </dd>
</dl>
<p>Although cardiovascular disease risks may be increased with oral contraceptive use after age 40 in healthy, non-smoking women (even with the newer low-dose formulations), there are also greater potential health risks associated with pregnancy in older women.</p>
<p>You should not take the pill if you suspect you are pregnant or have unexplained <span class="product-label-link" type="condition" conceptid="4129155" conceptname="Vaginal bleeding">vaginal bleeding</span>.</p>
<table>
<col width="100%">
<tbody class="Headless"><tr class="First Last"><td class="Botrule Lrule Rrule Toprule" valign="top"><p class="First"><span class="Bold">Cigarette smoking increases the risk of serious cardiovascular side effects from oral contraceptive use. This risk increases with age and with heavy smoking (15 or more cigarettes per day) and is quite marked in women over 35 years of age. Women who use oral contraceptives are strongly advised not to smoke.</span></p></td></tr></tbody>
</table>
<p>Most side effects of the pill are not serious. The most common such effects are <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>, <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>, <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> between menstrual periods, <span class="product-label-link" type="condition" conceptid="4134784" conceptname="Weight increased">weight gain</span>, <span class="product-label-link" type="condition" conceptid="4208409" conceptname="Breast tenderness">breast tenderness</span>, <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span>, and difficulty wearing contact lenses. These side effects, especially <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span> and <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>, may subside within the first three months of use.</p>
<p>The serious side effects of the pill occur very infrequently, especially if you are in good health and are young. However, you should know that the following medical conditions have been associated with or made worse by the pill:</p>
<dl>
<dt>1.</dt>
<dd>Blood clots in the legs (<span class="product-label-link" type="condition" conceptid="320741" conceptname="Thrombophlebitis">thrombophlebitis</span>) or lungs (<span class="product-label-link" type="condition" conceptid="440417" conceptname="Pulmonary embolism">pulmonary embolism</span>), stoppage or rupture of a blood vessel in the brain (<span class="product-label-link" type="condition" conceptid="381316" conceptname="Cerebrovascular accident">stroke</span>), blockage of blood vessels in the heart (<span class="product-label-link" type="condition" conceptid="4329847" conceptname="Myocardial infarction">heart attack</span> or <span class="product-label-link" type="condition" conceptid="321318" conceptname="Angina pectoris">angina pectoris</span>) or other organs of the body. As mentioned above, smoking increases the risk of <span class="product-label-link" type="condition" conceptid="4329847" conceptname="Myocardial infarction">heart attacks</span> and <span class="product-label-link" type="condition" conceptid="381316" conceptname="Cerebrovascular accident">strokes</span>, and subsequent serious medical consequences. </dd>
<dt>2.</dt>
<dd><span class="product-label-link" type="condition" conceptid="4322895" conceptname="Nodule of liver">Liver tumors</span>, which may rupture and cause severe <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span>. A possible but not definite association has been found with the pill and liver cancer. However, liver cancers are extremely rare. The chance of developing liver cancer from using the pill is thus even rarer. </dd>
<dt>3.</dt>
<dd>High blood pressure, although blood pressure usually returns to normal when the pill is stopped. </dd>
</dl>
<p>The symptoms associated with these serious side effects are discussed in the detailed leaflet given to you with your supply of pills. Notify your doctor or health care provider if you notice any unusual physical disturbances while taking the pill. In addition, drugs such as rifampin, as well as some anticonvulsants and some antibiotics may decrease oral contraceptive effectiveness.</p>
<p>There is conflict among studies regarding breast cancer and oral contraceptive use. Some studies have reported an increase in the risk of developing breast cancer, particularly at a younger age.</p>
<p>This increased risk appears to be related to duration of use. The majority of studies have found no overall increase in the risk of developing breast cancer. Some studies have found an increase in the incidence of cancer of the cervix in women who use oral contraceptives. However, this finding may be related to factors other than the use of oral contraceptives. There is insufficient evidence to rule out the possibility that pills may cause such cancers.</p>
<p>Taking the pill provides some important non-contraceptive benefits. These include less painful menstruation, less menstrual blood loss and <span class="product-label-link" type="condition" conceptid="439777" conceptname="Anemia">anemia</span>, fewer <span class="product-label-link" type="condition" conceptid="4003306" conceptname="Infection of pelvis">pelvic infections</span>, and fewer cancers of the ovary and the lining of the uterus.</p>
<p>Be sure to discuss any medical condition you may have with your doctor or health care provider. Your doctor or health care provider will take a medical and family history before prescribing oral contraceptives and will examine you. The physical examination may be delayed to another time if you request it and your doctor or health care provider believes that it is a good medical practice to postpone it. You should be reexamined at least once a year while taking oral contraceptives. The detailed patient information leaflet gives you further information which you should read and discuss with your doctor or health care provider.</p>
<p><span class="Bold">This product (like all oral contraceptives) is intended to prevent pregnancy. It does not protect against transmission of HIV (AIDS) and other <span class="product-label-link" type="condition" conceptid="440647" conceptname="Sexually transmitted infectious disease">sexually transmitted diseases</span> such as chlamydia, <span class="product-label-link" type="condition" conceptid="200319" conceptname="Herpetic infection of penis">genital herpes</span>, <span class="product-label-link" type="condition" conceptid="198075" conceptname="Condyloma acuminatum">genital warts</span>, <span class="product-label-link" type="condition" conceptid="433417" conceptname="Gonorrhea">gonorrhea</span>, <span class="product-label-link" type="condition" conceptid="194990" conceptname="Inflammatory disease of liver">hepatitis</span> B, and <span class="product-label-link" type="condition" conceptid="436033" conceptname="Syphilis">syphilis</span>.</span></p>
<p><span class="Bold"><span class="Underline">INSTRUCTIONS TO PATIENTS</span></span></p>
<p><span class="Bold"><span class="Underline">HOW TO TAKE THE PILL</span></span></p>
<p><span class="Bold">IMPORTANT POINTS TO REMEMBER</span></p>
<p><span class="Bold"><span class="Underline">BEFORE</span></span>YOU START TAKING YOUR PILLS:</p>
<p>1. BE SURE TO READ THESE DIRECTIONS: </p>
<p>Before you start taking your pills. </p>
<p>Anytime you are not sure what to do. </p>
<p>2. THE RIGHT WAY TO TAKE THE PILL IS TO TAKE ONE PILL EVERY DAY AT THE SAME TIME. </p>
<p>If you miss pills you could get pregnant. This includes starting the pack late.</p>
<p>The more pills you miss, the more likely you are to get pregnant. </p>
<p>3. MANY WOMEN HAVE SPOTTING OR LIGHT <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">BLEEDING</span>, OR MAY FEEL SICK TO THEIR STOMACH DURING THE FIRST 1 TO 3 PACKS OF PILLS.</p>
<p>If you feel sick to your stomach, do not stop taking the pill. The problem will usually go away. If it doesn't go away, check with your doctor or health care provider. </p>
<p>4. MISSING PILLS CAN ALSO CAUSE SPOTTING OR LIGHT <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">BLEEDING</span>, even when you make up these missed pills. </p>
<p>On the days you take 2 pills to make up for missed pills, you could also feel a little sick to your stomach. </p>
<p>5. IF YOU HAVE <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">VOMITING</span> OR <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">DIARRHEA</span>, for any reason, or IF YOU TAKE SOME MEDICINES, including some antibiotics, your pills may not work as well. </p>
<p>Use a back-up method (such as condoms, foam, or sponge) until you check with your doctor or health care provider. </p>
<p>6. IF YOU HAVE TROUBLE REMEMBERING TO TAKE THE PILL, talk to your doctor or health care provider about how to make pill-taking easier or about using another method of birth control. </p>
<p>7. IF YOU HAVE ANY QUESTIONS OR ARE UNSURE ABOUT THE INFORMATION IN THIS LEAFLET, call your doctor or health care provider. </p>
<p><span class="Bold"><span class="Underline">BEFORE</span> YOU START TAKING YOUR PILLS:</span></p>
<p>1. DECIDE WHAT TIME OF DAY YOU WANT TO TAKE YOUR PILL.</p>
<p>It is important to take it at about the same time every day.</p>
<p>2. LOOK AT YOUR PILL PACK: IT WILL HAVE 28 PILLS:</p>
<p>This <span class="Bold"><span class="Underline">28-pill pack</span></span> has 26 “active? [white and yellow] pills (with hormones) and 2 “inactive? [green] pills (without hormones).</p>
<p>3. ALSO FIND:</p>
<dl>
<dt>1.</dt>
<dd>where on the pack to start taking the pills, </dd>
<dt>2.</dt>
<dd>in what order to take the pills (follow the arrows) and </dd>
<dt>3.</dt>
<dd>the week numbers as shown in the picture below. </dd>
</dl>
<div class="Figure">
<a name="id1532"></a><img alt="<span class="product-label-link" type="condition" conceptid="443720" conceptname="Blister">blister</span> card tablet placement example graphic" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=39988aa6-8f68-40e8-9bdd-c40a3bdaad61&amp;name=644dec7a-1c0d-4161-a454-e280023f5735-03.jpg">
</div>
<p>4. BE SURE YOU HAVE READY AT ALL TIMES:</p>
<p>ANOTHER KIND OF BIRTH CONTROL (such as condoms, foam, or sponge) to use as a back-up in case you miss pills. </p>
<p>AN EXTRA, FULL PILL PACK.</p>
<p><span class="Bold">WHEN TO START THE <span class="Underline">FIRST</span> PACK OF PILLS</span></p>
<p>You have a choice of which day to start taking your first pack of pills. Decide with your doctor or healthcare provider which is the best day for you. Pick a time of day which will be easy to remember.</p>
<p><span class="Bold">DAY 1 START:</span></p>
<p>1. Pick the day label strip that starts with the first day of your period (this is the day you start <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> or spotting, even if it is almost midnight when the <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> begins).</p>
<p>2. Place this day label strip in the cycle tablet <span class="product-label-link" type="condition" conceptid="443720" conceptname="Blister">blister</span> card over the area that has the days of the week (starting with Sunday) imprinted.</p>
<div class="Figure">
<a name="id1545"></a><img alt="day label sticker placement example graphic" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=39988aa6-8f68-40e8-9bdd-c40a3bdaad61&amp;name=644dec7a-1c0d-4161-a454-e280023f5735-04.jpg">
</div>
<p>Note: If the first day of your period is a Sunday, you can skip steps #1 and #2.</p>
<p>3. Take the first “active? [white] pill of the first pack during the <span class="Underline">first 24 hours of your period</span>.</p>
<p>4. You will not need to use a back-up method of birth control, since you are starting the pill at the beginning of your period.</p>
<p><span class="Bold">SUNDAY START:</span></p>
<dl>
<dt>1.</dt>
<dd>Take the first “active? [white] pill of the first pack on the <span class="Underline">Sunday after your period starts</span>, even if you are still <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span>. If your period begins on Sunday, start the pack that same day. </dd>
<dt>2.</dt>
<dd>
<span class="Underline">Use another method of birth control</span> as a back-up method if you have sex anytime from the Sunday you start your first pack until the next Sunday (7 days). Condoms, foam, or the sponge are good back-up methods of birth control. </dd>
</dl>
<p><span class="Bold">WHAT TO DO DURING THE MONTH</span></p>
<p><span class="Bold">1. TAKE ONE PILL AT THE SAME TIME EVERY DAY UNTIL THE PACK IS EMPTY.</span></p>
<p>Do not skip pills even if you are spotting or <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> between monthly periods or feel sick to your stomach (<span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>). </p>
<p>Do not skip pills even if you do not have sex very often.</p>
<p><span class="Bold">2. WHEN YOU FINISH A PACK OR SWITCH YOUR BRAND OF PILLS:</span></p>
<p><span class="Bold"><span class="Underline">21 pills</span></span>: Wait 7 days to start the next pack. You will probably have your period during that week. Be sure that no more than 7 days pass between 21-day packs. </p>
<p><span class="Bold"><span class="Underline">28 pills</span></span>: Start the next pack on the day after your last pill. Do not wait any days between packs. </p>
<p><span class="Bold">WHAT TO DO IF YOU MISS PILLS</span></p>
<p>If you <span class="Bold">MISS 1</span> “active? [white] pill:</p>
<dl>
<dt>1.</dt>
<dd>Take it as soon as you remember. Take the next pill at your regular time. This means you take 2 pills in 1 day.</dd>
<dt>2.</dt>
<dd>You do not need to use a back-up birth control method if you have sex.</dd>
</dl>
<p>If you <span class="Bold">MISS 2</span> “active? [white] pills in a row in <span class="Bold">WEEK 1 OR WEEK 2</span> of your pack:</p>
<dl>
<dt>1.</dt>
<dd>Take 2 pills on the day you remember and 2 pills the next day.</dd>
<dt>2.</dt>
<dd>Then take 1 pill a day until you finish the pack.</dd>
<dt>3.</dt>
<dd>You MAY BECOME PREGNANT if you have sex in the <span class="Bold"><span class="Underline">7 days</span></span> after you miss pills.</dd>
</dl>
<p>You MUST use another birth control method (such as condoms, foam, or sponge) as a back-up method for those 7 days.</p>
<p>If you <span class="Bold">MISS 2</span> “active? [white] pills in a row in <span class="Bold">WEEK 3</span>:</p>
<p>1. <span class="Bold"><span class="Italics">If you are a Day 1 Starter:</span></span></p>
<p>THROW OUT the rest of the pill pack and start a new pack that same day.</p>
<p><span class="Bold"><span class="Italics">If you are a Sunday Starter:</span></span></p>
<p>Keep taking 1 pill every day until Sunday.</p>
<p>On Sunday, THROW OUT the rest of the pack and start a new pack of pills that same day. </p>
<p>2. You may not have your period this month but this is expected. However, if you miss your period 2 months in a row, call your doctor or health care provider because you might be pregnant. </p>
<p>3. You MAY BECOME PREGNANT if you have sex in the <span class="Bold"><span class="Underline">7 days</span></span> after you miss pills. You MUST use another birth control method (such as condoms, foam, or sponge) as a back-up method for those 7 days. </p>
<p>If you <span class="Bold">MISS 3 OR MORE</span> “active? [white] pills in a row (during the first 3 weeks):</p>
<p>1. <span class="Bold"><span class="Italics">If you are a Day 1 Starter:</span></span></p>
<p>THROW OUT the rest of the pill pack and start a new pack that same day.</p>
<p><span class="Bold"><span class="Italics">If you are a Sunday Starter:</span></span></p>
<p>Keep taking 1 pill every day until Sunday.</p>
<p>On Sunday, THROW OUT the rest of the pack and start a new pack of pills that same day. </p>
<p>2. You may not have your period this month but this is expected. However, if you miss your period 2 months in a row, call your doctor or health care provider because you might be pregnant. </p>
<p>3. You MAY BECOME PREGNANT if you have sex in the <span class="Bold"><span class="Underline">7 days</span></span> after you miss pills. You MUST use another birth control method (such as condoms, foam, or sponge) as a back-up method for those 7 days. </p>
<p><span class="Bold">A REMINDER FOR THOSE ON 28-DAY PACKS </span></p>
<p>If you forget any of the 2 [green] or 5 [yellow] pills in Week 4:</p>
<p>THROW AWAY the pills you missed.</p>
<p>Keep taking 1 pill each day until the pack is empty.</p>
<p>You do not need a back-up method.</p>
<p><span class="Bold">FINALLY, IF YOU ARE STILL NOT SURE WHAT TO DO ABOUT THE PILLS YOU HAVE MISSED:</span></p>
<p>Use a BACK-UP METHOD anytime you have sex.</p>
<p>KEEP TAKING ONE “ACTIVE? [WHITE] PILL EACH DAY until you can reach your doctor or health care provider.</p>
</div>
<div class="Section" data-sectionCode="42230-3">
<a name="i4i_patient_package_insert_id_24884cad-d4cd-4bd6-bcdf-4827b6bcc1cb"></a><a name="section-15"></a><p></p>
<h1>DETAILED PATIENT PACKAGE INSERT</h1>
<p class="First"><span class="Bold">VIORELE (Desogestrel and Ethinyl Estradiol Tablets USP, 0.15 mg/0.02 mg and Ethinyl Estradiol Tablets USP, 0.01 mg)</span></p>
<p><span class="Bold">This product (like all oral contraceptives) is intended to prevent pregnancy. It does not protect against <span class="product-label-link" type="condition" conceptid="439727" conceptname="Human immunodeficiency virus infection">HIV infection</span> (AIDS) and other <span class="product-label-link" type="condition" conceptid="440647" conceptname="Sexually transmitted infectious disease">sexually transmitted diseases</span>. </span></p>
<p><span class="Bold">Rx only</span></p>
<p><span class="Bold"><span class="Underline">PLEASE NOTE</span>: This labeling is revised from time to time as important new medical information becomes available. Therefore, please review this labeling carefully.</span></p>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_a6082c68-5eb1-4778-9ca2-209e86269dfc"></a><a name="section-15.1"></a><p></p>
<h2>DESCRIPTION</h2>
<p class="First">The following oral contraceptive product contains a combination of a progestin and estrogen, the two kinds of female hormones:</p>
<p>Each white tablet contains 0.15 mg desogestrel and 0.02 mg ethinyl estradiol USP. Each green tablet contains inert ingredients and each yellow tablet contains 0.01 mg ethinyl estradiol USP.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_aa606be1-88c3-4408-a148-f5192feb7a9e"></a><a name="section-15.2"></a><p></p>
<h2>INTRODUCTION</h2>
<p class="First">Any woman who considers using oral contraceptives (the birth control pill or the pill) should understand the benefits and risks of using this form of birth control. This leaflet will give you much of the information you will need to make this decision and will also help you determine if you are at risk of developing any of the serious side effects of the pill. It will tell you how to use the pill properly so that it will be as effective as possible. However, this leaflet is not a replacement for a careful discussion between you and your doctor or health care provider. You should discuss the information provided in this leaflet with him or her, both when you first start taking the pill and during your revisits. You should also follow your doctor's or health care provider's advice with regard to regular check-ups while you are on the pill.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_8bbe99af-ce67-4953-8153-5bb13527a04c"></a><a name="section-15.3"></a><p></p>
<h2>EFFECTIVENESS OF ORAL CONTRACEPTIVES</h2>
<p class="First">Oral contraceptives or “birth control pills? or “the pill? are used to prevent pregnancy and are more effective than other non-surgical methods of birth control. When they are taken correctly, the chance of becoming pregnant is less than 1% (1 pregnancy per 100 women per year of use) when used perfectly, without missing any pills. Typical failure rates are actually 5% per year. The chance of becoming pregnant increases with each missed pill during a menstrual cycle.</p>
<p>In comparison, typical failure rates for other methods of birth control during the first year of use are as follows:</p>
<table>
<col width="34%">
<col width="41%">
<tbody class="Headless">
<tr class="First">
<td class="Botrule Lrule Toprule" valign="top"><p class="First">Implants (2 or 6 capsules): &lt;1%</p></td>
<td class="Botrule Lrule Rrule Toprule" valign="top"><p class="First">Male sterilization: &lt;1%</p></td>
</tr>
<tr>
<td class="Botrule Lrule" valign="top"><p class="First">Injection: &lt;1%</p></td>
<td class="Botrule Lrule Rrule" valign="top"><p class="First">Cervical Cap with spermicides: 20 to 40%</p></td>
</tr>
<tr>
<td class="Botrule Lrule" valign="top"><p class="First">IUD: &lt; 1 to 2%</p></td>
<td class="Botrule Lrule Rrule" valign="top"><p class="First">Condom alone (male): 14%</p></td>
</tr>
<tr>
<td class="Botrule Lrule" valign="top"><p class="First">Diaphragm with spermicides: 20%</p></td>
<td class="Botrule Lrule Rrule" valign="top"><p class="First">Condom alone (female): 21%</p></td>
</tr>
<tr>
<td class="Botrule Lrule" valign="top"><p class="First">Spermicides alone: 26%</p></td>
<td class="Botrule Lrule Rrule" valign="top"><p class="First">Periodic abstinence: 25%</p></td>
</tr>
<tr>
<td class="Botrule Lrule" valign="top"><p class="First">Vaginal sponge: 20 to 40%</p></td>
<td class="Botrule Lrule Rrule" valign="top"><p class="First">Withdrawal: 19%</p></td>
</tr>
<tr class="Last">
<td class="Botrule Lrule" valign="top"><p class="First">Female sterilization: &lt;1%</p></td>
<td class="Botrule Lrule Rrule" valign="top"><p class="First">No methods: 85%.</p></td>
</tr>
</tbody>
</table>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_a8ba59ca-5705-4c8c-b7c4-2923ffc11677"></a><a name="section-15.4"></a><p></p>
<h2>WHO SHOULD NOT TAKE ORAL CONTRACEPTIVES</h2>
<table>
<col width="100%">
<tbody class="Headless"><tr class="First Last"><td class="Botrule Lrule Rrule Toprule" valign="top"><p class="First"><span class="Bold">Cigarette smoking increases the risk of serious cardiovascular side effects from oral contraceptive use. This risk increases with age and with heavy smoking (15 or more cigarettes per day) and is quite marked in women over 35 years of age. Women who use oral contraceptives are strongly advised not to smoke.</span></p></td></tr></tbody>
</table>
<p class="First">Some women should not use the pill. For example, you should not take the pill if you are pregnant or think you may be pregnant. You should also not use the pill if you have any of the following conditions:</p>
<dl>
<dt>•</dt>
<dd>A history of <span class="product-label-link" type="condition" conceptid="4329847" conceptname="Myocardial infarction">heart attack</span> or <span class="product-label-link" type="condition" conceptid="381316" conceptname="Cerebrovascular accident">stroke</span> </dd>
<dt>•</dt>
<dd>Blood clots in the legs (<span class="product-label-link" type="condition" conceptid="320741" conceptname="Thrombophlebitis">thrombophlebitis</span>), lungs (<span class="product-label-link" type="condition" conceptid="440417" conceptname="Pulmonary embolism">pulmonary embolism</span>), or eyes </dd>
<dt>•</dt>
<dd>A history of blood clots in the deep veins of your legs </dd>
<dt>•</dt>
<dd><span class="product-label-link" type="condition" conceptid="77670" conceptname="Chest pain">Chest pain</span> (<span class="product-label-link" type="condition" conceptid="321318" conceptname="Angina pectoris">angina pectoris</span>) </dd>
<dt>•</dt>
<dd>Known or suspected breast cancer or cancer of the lining of the uterus, cervix or vagina </dd>
<dt>•</dt>
<dd>Unexplained <span class="product-label-link" type="condition" conceptid="4129155" conceptname="Vaginal bleeding">vaginal bleeding</span> (until a diagnosis is reached by your doctor) </dd>
<dt>•</dt>
<dd>Yellowing of the whites of the eyes or of the skin (<span class="product-label-link" type="condition" conceptid="137977" conceptname="Jaundice">jaundice</span>) during pregnancy or during previous use of the pill </dd>
<dt>•</dt>
<dd><span class="product-label-link" type="condition" conceptid="4322895" conceptname="Nodule of liver">Liver tumor</span> (benign or cancerous) </dd>
<dt>•</dt>
<dd>Known or suspected pregnancy. </dd>
</dl>
<p>Tell your doctor or health care provider if you have ever had any of these conditions. Your doctor or health care provider can recommend another method of birth control.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_c6342414-24f8-4f0b-8110-eafb0b8b5f30"></a><a name="section-15.5"></a><p></p>
<h2>OTHER CONSIDERATIONS BEFORE TAKING ORAL CONTRACEPTIVES</h2>
<p class="First">Tell your doctor or health care provider if you have:</p>
<dl>
<dt>•</dt>
<dd>Breast <span class="product-label-link" type="condition" conceptid="4101098" conceptname="Nodule">nodules</span>, fibrocystic disease of the breast, an abnormal breast x-ray or mammogram </dd>
<dt>•</dt>
<dd><span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">Diabetes</span> </dd>
<dt>•</dt>
<dd>Elevated <span class="product-label-link" type="condition" conceptid="4224820" conceptname="Cholesterol">cholesterol</span> or triglycerides </dd>
<dt>•</dt>
<dd>High blood pressure </dd>
<dt>•</dt>
<dd><span class="product-label-link" type="condition" conceptid="318736" conceptname="Migraine">Migraine</span> or other <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headaches</span> or <span class="product-label-link" type="condition" conceptid="380378" conceptname="Epilepsy">epilepsy</span> </dd>
<dt>•</dt>
<dd>Mental <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depression</span> </dd>
<dt>•</dt>
<dd>Gallbladder, heart, or kidney disease </dd>
<dt>•</dt>
<dd>History of scanty or irregular menstrual periods. </dd>
</dl>
<p>Women with any of these conditions should be checked often by their doctor or health care provider if they choose to use oral contraceptives. </p>
<p>Also, be sure to inform your doctor or health care provider if you smoke or are on any medications.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_1e5e7e01-037b-47fe-90d0-1679bb37ca35"></a><a name="section-15.6"></a><p></p>
<h2>RISKS OF TAKING ORAL CONTRACEPTIVES </h2>
<p class="First"><span class="Bold">1. Risk of developing blood clots</span></p>
<p>Blood clots and blockage of blood vessels are one of the most serious side effects of taking oral contraceptives and can cause <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span> or serious <span class="product-label-link" type="condition" conceptid="4052648" conceptname="Disability">disability</span>. In particular, a clot in the leg can cause <span class="product-label-link" type="condition" conceptid="320741" conceptname="Thrombophlebitis">thrombophlebitis</span> and a clot that travels to the lungs can cause a sudden blockage of the vessel carrying blood to the lungs. The risks of these side effects may be greater with desogestrel-containing oral contraceptives such as desogestrel/ethinyl estradiol and ethinyl estradiol than with certain other low-dose pills. Rarely, clots occur in the blood vessels of the eye and may cause <span class="product-label-link" type="condition" conceptid="377551" conceptname="Blind hypertensive eye">blindness</span>, <span class="product-label-link" type="condition" conceptid="373474" conceptname="Diplopia">double vision</span>, or impaired vision.</p>
<p>If you take oral contraceptives and need elective surgery, need to stay in bed for a prolonged illness or have recently delivered a baby, you may be at risk of developing blood clots. You should consult your doctor or health care provider about stopping oral contraceptives three to four weeks before surgery and not taking oral contraceptives for two weeks after surgery or during bed rest. You should also not take oral contraceptives soon after delivery of a baby. It is advisable to wait for at least four weeks after delivery if you are not breast feeding or four weeks after a second trimester abortion. If you are breast feeding, you should wait until you have weaned your child before using the pill (see Breast Feeding in <span class="Bold"><a href="#i4i_section_id_90129076-ab56-4692-aa9e-0412ebe8c9f9">GENERAL PRECAUTIONS</a></span>).</p>
<p>The risk of circulatory disease in oral contraceptive users may be higher in users of high dose pills and may be greater with longer duration of oral contraceptive use. In addition, some of these increased risks may continue for a number of years after stopping oral contraceptives. The risk of venous thromboembolic disease associated with oral contraceptives does not increase with length of use and disappears after pill use is stopped. The risk of abnormal blood clotting increases with age in both users and non-users of oral contraceptives, but the increased risk from the oral contraceptive appears to be present at all ages. For women aged 20 to 44 it is estimated that about 1 in 2000 using oral contraceptives will be hospitalized each year because of abnormal clotting. Among non-users in the same age group, about 1 in 20,000 would be hospitalized each year. For oral contraceptive users in general, it has been estimated that in women between the ages of 15 and 34 the risk of <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span> due to a circulatory disorder is about 1 in 12,000 per year, whereas for non-users the rate is about 1 in 50,000 per year. In the age group 35 to 44, the risk is estimated to be about 1 in 2500 per year for oral contraceptive users and about 1 in 10,000 per year for non-users.</p>
<p><span class="Bold">2. <span class="product-label-link" type="condition" conceptid="4329847" conceptname="Myocardial infarction">Heart attacks</span> and <span class="product-label-link" type="condition" conceptid="381316" conceptname="Cerebrovascular accident">strokes</span></span></p>
<p>Oral contraceptives may increase the tendency to develop <span class="product-label-link" type="condition" conceptid="381316" conceptname="Cerebrovascular accident">strokes</span> (stoppage or rupture of blood vessels in the brain) and <span class="product-label-link" type="condition" conceptid="321318" conceptname="Angina pectoris">angina pectoris</span> and <span class="product-label-link" type="condition" conceptid="4329847" conceptname="Myocardial infarction">heart attacks</span> (blockage of blood vessels in the heart). Any of these conditions can cause <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span> or serious <span class="product-label-link" type="condition" conceptid="4052648" conceptname="Disability">disability</span>.</p>
<p>Smoking greatly increases the possibility of suffering <span class="product-label-link" type="condition" conceptid="4329847" conceptname="Myocardial infarction">heart attacks</span> and <span class="product-label-link" type="condition" conceptid="381316" conceptname="Cerebrovascular accident">strokes</span>. Furthermore, smoking and the use of oral contraceptives greatly increase the chances of developing and dying of heart disease.</p>
<p><span class="Bold">3. <span class="product-label-link" type="condition" conceptid="192353" conceptname="Disorder of gallbladder">Gallbladder disease</span></span></p>
<p>Oral contraceptive users probably have a greater risk than non-users of having <span class="product-label-link" type="condition" conceptid="192353" conceptname="Disorder of gallbladder">gallbladder disease</span>, although this risk may be related to pills containing high doses of estrogens.</p>
<p><span class="Bold">4. <span class="product-label-link" type="condition" conceptid="4322895" conceptname="Nodule of liver">Liver tumors</span></span></p>
<p>In rare cases, oral contraceptives can cause benign but dangerous <span class="product-label-link" type="condition" conceptid="4322895" conceptname="Nodule of liver">liver tumors</span>. These benign <span class="product-label-link" type="condition" conceptid="4322895" conceptname="Nodule of liver">liver tumors</span> can rupture and cause fatal internal <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span>. In addition, a possible but not definite association has been found with the pill and liver cancers in two studies, in which a few women who developed these very rare cancers were found to have used oral contraceptives for long periods. However, liver cancers are extremely rare. The chance of developing liver cancer from using the pill is thus even rarer.</p>
<p><span class="Bold">5. Cancer of the reproductive organs and breasts</span></p>
<p>There is conflict among studies regarding breast cancer and oral contraceptive use. Some studies have reported an increase in the risk of developing breast cancer, particularly at a younger age. This increased risk appears to be related to duration of use. The majority of studies have found no overall increase in the risk of developing breast cancer.</p>
<p>Some studies have found an increase in the incidence of cancer of the cervix in women who use oral contraceptives. However, this finding may be related to factors other than the use of oral contraceptives. There is insufficient evidence to rule out the possibility that pills may cause such cancers.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_a9c97617-3380-473a-b412-10016177e7ce"></a><a name="section-15.7"></a><p></p>
<h2>ESTIMATED RISK OF <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">DEATH</span> FROM A BIRTH CONTROL METHOD OR PREGNANCY</h2>
<p class="First">All methods of birth control and pregnancy are associated with a risk of developing certain diseases which may lead to <span class="product-label-link" type="condition" conceptid="4052648" conceptname="Disability">disability</span> or <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span>. An estimate of the number of <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">deaths</span> associated with different methods of birth control and pregnancy has been calculated and is shown in the following table.</p>
<a name="_RefIDF80129EA819A42C89792BF91799EF24E"></a><table>
<caption><span>ANNUAL NUMBER OF BIRTH-RELATED OR METHOD-RELATED <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">DEATHS</span> ASSOCIATED WITH CONTROL OF FERTILITY PER 100,000 NON-STERILE WOMEN, BY FERTILITY CONTROL METHOD ACCORDING TO AGE </span></caption>
<col width="33%">
<col width="8%">
<col width="8%">
<col width="8%">
<col width="8%">
<col width="8%">
<col width="8%">
<tfoot><tr><td colspan="7" align="left"><dl class="Footnote">
<dt><a name="footnote-9" href="#footnote-reference-9">*</a></dt>
<dd><span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">Deaths</span> are birth related</dd>
<dt><a name="footnote-10" href="#footnote-reference-10">†</a></dt>
<dd><span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">Deaths</span> are method related</dd>
</dl></td></tr></tfoot>
<tbody class="Headless">
<tr class="First">
<td class="Botrule Lrule Toprule" valign="top"><p class="First"><span class="Bold">Method of control and outcome</span></p></td>
<td class="Botrule Lrule Toprule" align="center" valign="top"><p class="First"><span class="Bold">15-19</span></p></td>
<td class="Botrule Lrule Toprule" align="center" valign="top"><p class="First"><span class="Bold">20-24</span></p></td>
<td class="Botrule Lrule Toprule" align="center" valign="top"><p class="First"><span class="Bold">25-29</span></p></td>
<td class="Botrule Lrule Toprule" align="center" valign="top"><p class="First"><span class="Bold">30-34</span></p></td>
<td class="Botrule Lrule Toprule" align="center" valign="top"><p class="First"><span class="Bold">35-39</span></p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><p class="First"><span class="Bold">40-44</span></p></td>
</tr>
<tr>
<td class="Botrule Lrule" valign="top"><p class="First">No fertility control methods<a name="footnote-reference-9" href="#footnote-9" class="Sup">*</a></p></td>
<td class="Botrule Lrule" align="center" valign="top"><p class="First">7.0</p></td>
<td class="Botrule Lrule" align="center" valign="top"><p class="First">7.4</p></td>
<td class="Botrule Lrule" align="center" valign="top"><p class="First">9.1</p></td>
<td class="Botrule Lrule" align="center" valign="top"><p class="First">14.8</p></td>
<td class="Botrule Lrule" align="center" valign="top"><p class="First">25.7</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="top"><p class="First">28.2</p></td>
</tr>
<tr>
<td class="Botrule Lrule" valign="top"><p class="First">Oral contraceptives non-smoker<a name="footnote-reference-10" href="#footnote-10" class="Sup">†</a></p></td>
<td class="Botrule Lrule" align="center" valign="top"><p class="First">0.3</p></td>
<td class="Botrule Lrule" align="center" valign="top"><p class="First">0.5</p></td>
<td class="Botrule Lrule" align="center" valign="top"><p class="First">0.9</p></td>
<td class="Botrule Lrule" align="center" valign="top"><p class="First">1.9</p></td>
<td class="Botrule Lrule" align="center" valign="top"><p class="First">13.8</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="top"><p class="First">31.6</p></td>
</tr>
<tr>
<td class="Botrule Lrule" valign="top"><p class="First">Oral contraceptives smoker<a href="#footnote-10" class="Sup">†</a></p></td>
<td class="Botrule Lrule" align="center" valign="top"><p class="First">2.2</p></td>
<td class="Botrule Lrule" align="center" valign="top"><p class="First">3.4</p></td>
<td class="Botrule Lrule" align="center" valign="top"><p class="First">6.6</p></td>
<td class="Botrule Lrule" align="center" valign="top"><p class="First">13.5</p></td>
<td class="Botrule Lrule" align="center" valign="top"><p class="First">51.1</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="top"><p class="First">117.2</p></td>
</tr>
<tr>
<td class="Botrule Lrule" valign="top"><p class="First">IUD<a href="#footnote-10" class="Sup">†</a></p></td>
<td class="Botrule Lrule" align="center" valign="top"><p class="First">0.8</p></td>
<td class="Botrule Lrule" align="center" valign="top"><p class="First">0.8</p></td>
<td class="Botrule Lrule" align="center" valign="top"><p class="First">1.0</p></td>
<td class="Botrule Lrule" align="center" valign="top"><p class="First">1.0</p></td>
<td class="Botrule Lrule" align="center" valign="top"><p class="First">1.4</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="top"><p class="First">1.4</p></td>
</tr>
<tr>
<td class="Botrule Lrule" valign="top"><p class="First">Condom<a href="#footnote-9" class="Sup">*</a></p></td>
<td class="Botrule Lrule" align="center" valign="top"><p class="First">1.1</p></td>
<td class="Botrule Lrule" align="center" valign="top"><p class="First">1.6</p></td>
<td class="Botrule Lrule" align="center" valign="top"><p class="First">0.7</p></td>
<td class="Botrule Lrule" align="center" valign="top"><p class="First">0.2</p></td>
<td class="Botrule Lrule" align="center" valign="top"><p class="First">0.3</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="top"><p class="First">0.4</p></td>
</tr>
<tr>
<td class="Botrule Lrule" valign="top"><p class="First">Diaphragm/spermicide<a href="#footnote-9" class="Sup">*</a></p></td>
<td class="Botrule Lrule" align="center" valign="top"><p class="First">1.9</p></td>
<td class="Botrule Lrule" align="center" valign="top"><p class="First">1.2</p></td>
<td class="Botrule Lrule" align="center" valign="top"><p class="First">1.2</p></td>
<td class="Botrule Lrule" align="center" valign="top"><p class="First">1.3</p></td>
<td class="Botrule Lrule" align="center" valign="top"><p class="First">2.2</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="top"><p class="First">2.8</p></td>
</tr>
<tr class="Last">
<td class="Botrule Lrule" valign="top"><p class="First">Periodic abstinence<a href="#footnote-9" class="Sup">*</a></p></td>
<td class="Botrule Lrule" align="center" valign="top"><p class="First">2.5</p></td>
<td class="Botrule Lrule" align="center" valign="top"><p class="First">1.6</p></td>
<td class="Botrule Lrule" align="center" valign="top"><p class="First">1.6</p></td>
<td class="Botrule Lrule" align="center" valign="top"><p class="First">1.7</p></td>
<td class="Botrule Lrule" align="center" valign="top"><p class="First">2.9</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="top"><p class="First">3.6</p></td>
</tr>
</tbody>
</table>
<p>In the above table, the risk of <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span> from any birth control method is less than the risk of childbirth, except for oral contraceptive users over the age of 35 who smoke and pill users over the age of 40 even if they do not smoke. It can be seen in the table that for women aged 15 to 39, the risk of <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span> was highest with pregnancy (7 to 26 <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">deaths</span> per 100,000 women, depending on age). Among pill users who do not smoke, the risk of <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span> is always lower than that associated with pregnancy for any age group, although over the age of 40, the risk increases to 32 <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">deaths</span> per 100,000 women, compared to 28 associated with pregnancy at that age. However, for pill users who smoke and are over the age of 35, the estimated number of <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">deaths</span> exceeds those for other methods of birth control. If a woman is over the age of 40 and smokes, her estimated risk of <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span> is four times higher (117/100,000 women) than the estimated risk associated with pregnancy (28/100,000 women) in that age group.</p>
<p>The suggestion that women over 40 who do not smoke should not take oral contraceptives is based on information from older, high-dose pills and on less selective use of pills than is practiced today. An Advisory Committee of the FDA discussed this issue in 1989 and recommended that the benefits of oral contraceptive use by healthy, non-smoking women over 40 years of age may outweigh the possible risks. However, all women, especially older women, are cautioned to use the lowest dose pill that is effective.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_275167b4-da6d-4555-975a-0043e668bb99"></a><a name="section-15.8"></a><p></p>
<h2>WARNING SIGNALS</h2>
<p class="First">If any of these adverse effects occur while you are taking oral contraceptives, call your doctor or health care provider immediately:</p>
<dl>
<dt>•</dt>
<dd>Sharp <span class="product-label-link" type="condition" conceptid="77670" conceptname="Chest pain">chest pain</span>, <span class="product-label-link" type="condition" conceptid="254761" conceptname="Cough">coughing</span> of blood, or sudden <span class="product-label-link" type="condition" conceptid="312437" conceptname="Dyspnea">shortness of breath</span> (indicating a possible clot in the lung) </dd>
<dt>•</dt>
<dd><span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">Pain</span> in the calf (indicating a possible clot in the leg) </dd>
<dt>•</dt>
<dd>Crushing <span class="product-label-link" type="condition" conceptid="77670" conceptname="Chest pain">chest pain</span> or heaviness in the chest (indicating a possible <span class="product-label-link" type="condition" conceptid="4329847" conceptname="Myocardial infarction">heart attack</span>) </dd>
<dt>•</dt>
<dd>Sudden severe <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span> or <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>, <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">dizziness</span> or <span class="product-label-link" type="condition" conceptid="135360" conceptname="Syncope">fainting</span>, disturbances of vision or speech, <span class="product-label-link" type="condition" conceptid="437113" conceptname="Asthenia">weakness</span>, or <span class="product-label-link" type="condition" conceptid="4151171" conceptname="Numbness of limbs">numbness</span> in an arm or leg (indicating a possible <span class="product-label-link" type="condition" conceptid="381316" conceptname="Cerebrovascular accident">stroke</span>) </dd>
<dt>•</dt>
<dd>Sudden partial or complete <span class="product-label-link" type="condition" conceptid="377551" conceptname="Blind hypertensive eye">loss of vision</span> (indicating a possible clot in the eye) </dd>
<dt>•</dt>
<dd><span class="product-label-link" type="condition" conceptid="80767" conceptname="Breast lump">Breast lumps</span> (indicating possible breast cancer or fibrocystic disease of the breast; ask your doctor or health care provider to show you how to examine your breasts) </dd>
<dt>•</dt>
<dd>Severe <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span> or <span class="product-label-link" type="condition" conceptid="4082445" conceptname="Tenderness">tenderness</span> in the stomach area (indicating a possibly ruptured <span class="product-label-link" type="condition" conceptid="4322895" conceptname="Nodule of liver">liver tumor</span>) </dd>
<dt>•</dt>
<dd>Difficulty in sleeping, <span class="product-label-link" type="condition" conceptid="437113" conceptname="Asthenia">weakness</span>, lack of energy, <span class="product-label-link" type="condition" conceptid="4223659" conceptname="Fatigue">fatigue</span>, or change in mood (possibly indicating severe <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depression</span>) </dd>
<dt>•</dt>
<dd><span class="product-label-link" type="condition" conceptid="137977" conceptname="Jaundice">Jaundice</span> or a yellowing of the skin or eyeballs, accompanied frequently by <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">fever</span>, <span class="product-label-link" type="condition" conceptid="4223659" conceptname="Fatigue">fatigue</span>, loss of appetite, dark colored urine, or light colored bowel movements (indicating possible liver problems).</dd>
</dl>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_9db5d13f-9157-4b30-9595-fa9048bfec4e"></a><a name="section-15.9"></a><p></p>
<h2>SIDE EFFECTS OF ORAL CONTRACEPTIVES </h2>
<p class="First"><span class="Bold">1. <span class="product-label-link" type="condition" conceptid="4129155" conceptname="Vaginal bleeding">Vaginal bleeding</span></span></p>
<p>Irregular <span class="product-label-link" type="condition" conceptid="4129155" conceptname="Vaginal bleeding">vaginal bleeding</span> or spotting may occur while you are taking the pills. Irregular <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> may vary from slight staining between menstrual periods to breakthrough <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> which is a flow much like a regular period. Irregular <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> occurs most often during the first few months of oral contraceptive use, but may also occur after you have been taking the pill for some time. Such <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> may be temporary and usually does not indicate any serious problems. It is important to continue taking your pills on schedule. If the <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> occurs in more than one cycle or lasts for more than a few days, talk to your doctor or health care provider.</p>
<p><span class="Bold">2. Contact lenses</span></p>
<p>If you wear contact lenses and notice a change in vision or an inability to wear your lenses, contact your doctor or health care provider.</p>
<p><span class="Bold">3. <span class="product-label-link" type="condition" conceptid="4125002" conceptname="Idiopathic fluid retention">Fluid retention</span></span></p>
<p>Oral contraceptives may cause <span class="product-label-link" type="condition" conceptid="433595" conceptname="Edema">edema</span> (<span class="product-label-link" type="condition" conceptid="4125002" conceptname="Idiopathic fluid retention">fluid retention</span>) with <span class="product-label-link" type="condition" conceptid="4275722" conceptname="Swelling">swelling</span> of the fingers or ankles and may raise your blood pressure. If you experience <span class="product-label-link" type="condition" conceptid="4125002" conceptname="Idiopathic fluid retention">fluid retention</span>, contact your doctor or health care provider.</p>
<p><span class="Bold">4. <span class="product-label-link" type="condition" conceptid="4264234" conceptname="Chloasma">Melasma</span></span></p>
<p>A spotty darkening of the skin is possible, particularly of the face.</p>
<p><span class="Bold">5. Other side effects</span></p>
<p>Other side effects may include <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span> and <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>, change in appetite, <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span>, <span class="product-label-link" type="condition" conceptid="436817" conceptname="Feeling nervous">nervousness</span>, <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depression</span>, <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">dizziness</span>, loss of scalp hair, <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span>, and <span class="product-label-link" type="condition" conceptid="4081648" conceptname="Acute vaginitis">vaginal infections</span>. </p>
<p>If any of these side effects bother you, call your doctor or health care provider.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_90129076-ab56-4692-aa9e-0412ebe8c9f9"></a><a name="section-15.10"></a><p></p>
<h2>GENERAL PRECAUTIONS</h2>
<p class="First"><span class="Bold">1. Missed periods and use of oral contraceptives before or during early pregnancy</span></p>
<p>There may be times when you may not menstruate regularly after you have completed taking a cycle of pills. If you have taken your pills regularly and miss one menstrual period, continue taking your pills for the next cycle but be sure to inform your doctor or health care provider before doing so. If you have not taken the pills daily as instructed and missed a menstrual period, or if you missed two consecutive menstrual periods, you may be pregnant. Check with your doctor or health care provider immediately to determine whether you are pregnant. Do not continue to take oral contraceptives until you are sure you are not pregnant, but continue to use another method of contraception.</p>
<p>There is no conclusive evidence that oral contraceptive use is associated with an increase in <span class="product-label-link" type="condition" conceptid="4029540" conceptname="Congenital anomaly">birth defects</span>, when taken inadvertently during early pregnancy. Previously, a few studies had reported that oral contraceptives might be associated with <span class="product-label-link" type="condition" conceptid="4029540" conceptname="Congenital anomaly">birth defects</span>, but these studies have not been confirmed. Nevertheless, oral contraceptives or any other drugs should not be used during pregnancy unless clearly necessary and prescribed by your doctor or health care provider. You should check with your doctor or health care provider about risks to your unborn child of any medication taken during pregnancy.</p>
<p><span class="Bold">2. While breast feeding</span></p>
<p>If you are breast feeding, consult your doctor or health care provider before starting oral contraceptives. Some of the drug will be passed on to the child in the milk. A few adverse effects on the child have been reported, including yellowing of the skin (<span class="product-label-link" type="condition" conceptid="137977" conceptname="Jaundice">jaundice</span>) and <span class="product-label-link" type="condition" conceptid="78474" conceptname="Hypertrophy of breast">breast enlargement</span>. In addition, oral contraceptives may decrease the amount and quality of your milk. If possible, do not use oral contraceptives while breast feeding. You should use another method of contraception since breast feeding provides only partial protection from becoming pregnant and this partial protection decreases significantly as you breast feed for longer periods of time. You should consider starting oral contraceptives only after you have weaned your child completely.</p>
<p><span class="Bold">3. Laboratory tests</span></p>
<p>If you are scheduled for any laboratory tests, tell your doctor or health care provider you are taking birth control pills. Certain blood tests may be affected by birth control pills.</p>
<p><span class="Bold">4. Drug interactions</span></p>
<p>Certain drugs may interact with birth control pills to make them less effective in preventing pregnancy or cause an increase in breakthrough <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span>. Such drugs include rifampin, drugs used for <span class="product-label-link" type="condition" conceptid="380378" conceptname="Epilepsy">epilepsy</span> such as barbiturates (for example, phenobarbital), phenytoin (Dilantin<span class="Sup">®</span> is one brand of this drug), phenylbutazone (Butazolidin<span class="Sup">®</span> is one brand), and possibly certain antibiotics. You may need to use additional contraception when you take drugs which can make oral contraceptives less effective.</p>
<p>Birth control pills may interact with lamotrigine, an anticonvulsant used for <span class="product-label-link" type="condition" conceptid="380378" conceptname="Epilepsy">epilepsy</span>. This may increase the risk of <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizures</span>, so your physician may need to adjust the dose of lamotrigine.</p>
<p>Some medicines may make birth control pill less effective, including: </p>
<dl>
<dt>•</dt>
<dd>Barbiturates </dd>
<dt>•</dt>
<dd>Bosentan </dd>
<dt>•</dt>
<dd>Carbamazepine </dd>
<dt>•</dt>
<dd>Felbamate </dd>
<dt>•</dt>
<dd>Griseofulvin </dd>
<dt>•</dt>
<dd>Oxcarbazepine </dd>
<dt>•</dt>
<dd>Phenytoin </dd>
<dt>•</dt>
<dd>Rifampin </dd>
<dt>•</dt>
<dd>St. John’s wort </dd>
<dt>•</dt>
<dd>Topiramate </dd>
</dl>
<p>As with all prescription products, you should notify your healthcare provider of any other medicines and herbal products you are taking. You may need to use a barrier contraceptive when you take drugs or products that can make birth control pills less effective.</p>
<p><span class="Bold">5. <span class="product-label-link" type="condition" conceptid="440647" conceptname="Sexually transmitted infectious disease">Sexually transmitted diseases</span></span></p>
<p><span class="Bold">This product (like all oral contraceptives) is intended to prevent pregnancy. It does not protect against transmission of HIV (AIDS) and other <span class="product-label-link" type="condition" conceptid="440647" conceptname="Sexually transmitted infectious disease">sexually transmitted diseases</span> such as chlamydia, <span class="product-label-link" type="condition" conceptid="200319" conceptname="Herpetic infection of penis">genital herpes</span>, <span class="product-label-link" type="condition" conceptid="198075" conceptname="Condyloma acuminatum">genital warts</span>, <span class="product-label-link" type="condition" conceptid="433417" conceptname="Gonorrhea">gonorrhea</span>, <span class="product-label-link" type="condition" conceptid="194990" conceptname="Inflammatory disease of liver">hepatitis</span> B, and <span class="product-label-link" type="condition" conceptid="436033" conceptname="Syphilis">syphilis</span>.</span></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_9d66d31b-13a5-4d31-86aa-ea1b4860d854"></a><a name="section-15.11"></a><p></p>
<h2><span class="Underline">HOW TO TAKE THE PILL</span></h2>
<p class="First"><span class="Bold">IMPORTANT POINTS TO REMEMBER</span></p>
<p><span class="Underline">BEFORE</span> YOU START TAKING YOUR PILLS:</p>
<p>1. BE SURE TO READ THESE DIRECTIONS: </p>
<p>Before you start taking your pills. </p>
<p>Anytime you are not sure what to do. </p>
<p>2. THE RIGHT WAY TO TAKE THE PILL IS TO TAKE ONE PILL EVERY DAY AT THE SAME TIME. </p>
<p>If you miss pills you could get pregnant. This includes starting the pack late.</p>
<p>The more pills you miss, the more likely you are to get pregnant. </p>
<p>3. MANY WOMEN HAVE SPOTTING OR LIGHT <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">BLEEDING</span>, OR MAY FEEL SICK TO THEIR STOMACH DURING THE FIRST 1 TO 3 PACKS OF PILLS.</p>
<p>If you feel sick to your stomach, do not stop taking the pill. The problem will usually go away. If it doesn't go away, check with your doctor or health care provider. </p>
<p>4. MISSING PILLS CAN ALSO CAUSE SPOTTING OR LIGHT <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">BLEEDING</span>, even when you make up these missed pills. </p>
<p>On the days you take 2 pills to make up for missed pills, you could also feel a little sick to your stomach. </p>
<p>5. IF YOU HAVE <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">VOMITING</span> OR <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">DIARRHEA</span>, for any reason, or IF YOU TAKE SOME MEDICINES, including some antibiotics, your pills may not work as well. </p>
<p>Use a back-up method (such as condoms, foam, or sponge) until you check with your doctor or health care provider. </p>
<p>6. IF YOU HAVE TROUBLE REMEMBERING TO TAKE THE PILL, talk to your doctor or health care provider about how to make pill-taking easier or about using another method of birth control. </p>
<p>7. IF YOU HAVE ANY QUESTIONS OR ARE UNSURE ABOUT THE INFORMATION IN THIS LEAFLET, call your doctor or health care provider. </p>
<p><span class="Bold"><span class="Underline">BEFORE</span> YOU START TAKING YOUR PILLS:</span></p>
<p>1. DECIDE WHAT TIME OF DAY YOU WANT TO TAKE YOUR PILL.</p>
<p>It is important to take it at about the same time every day.</p>
<p>2. LOOK AT YOUR PILL PACK: IT WILL HAVE 28 PILLS:</p>
<p>This <span class="Bold"><span class="Underline">28-pill pack</span></span> has 26 “active? [white and yellow] pills (with hormones) and 2 “inactive? [green] pills (without hormones).</p>
<p>3. ALSO FIND:</p>
<dl>
<dt>1.</dt>
<dd>where on the pack to start taking the pills, </dd>
<dt>2.</dt>
<dd>in what order to take the pills (follow the arrows) and </dd>
<dt>3.</dt>
<dd>the week numbers as shown in the picture below. </dd>
</dl>
<div class="Figure">
<a name="id1929"></a><img alt="<span class="product-label-link" type="condition" conceptid="443720" conceptname="Blister">blister</span> card tablet placement example graphic" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=39988aa6-8f68-40e8-9bdd-c40a3bdaad61&amp;name=644dec7a-1c0d-4161-a454-e280023f5735-05.jpg">
</div>
<p>4. BE SURE YOU HAVE READY AT ALL TIMES:</p>
<p>ANOTHER KIND OF BIRTH CONTROL (such as condoms, foam, or sponge) to use as a back-up in case you miss pills. </p>
<p>AN EXTRA, FULL PILL PACK.</p>
<p><span class="Bold">WHEN TO START THE <span class="Underline">FIRST</span> PACK OF PILLS</span></p>
<p>You have a choice of which day to start taking your first pack of pills. Decide with your doctor or healthcare provider which is the best day for you. Pick a time of day which will be easy to remember.</p>
<p><span class="Bold">DAY 1 START:</span></p>
<p>1. Pick the day label strip that starts with the first day of your period (this is the day you start <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> or spotting, even if it is almost midnight when the <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> begins).</p>
<p>2. Place this day label strip in the cycle tablet <span class="product-label-link" type="condition" conceptid="443720" conceptname="Blister">blister</span> card over the area that has the days of the week (starting with Sunday) imprinted.</p>
<div class="Figure">
<a name="id1942"></a><img alt="day label sticker placement example graphic" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=39988aa6-8f68-40e8-9bdd-c40a3bdaad61&amp;name=644dec7a-1c0d-4161-a454-e280023f5735-06.jpg">
</div>
<p>Note: If the first day of your period is a Sunday, you can skip steps #1 and #2.</p>
<p>3. Take the first “active? [white] pill of the first pack during the <span class="Underline">first 24 hours of your period</span>.</p>
<p>4. You will not need to use a back-up method of birth control, since you are starting the pill at the beginning of your period.</p>
<p><span class="Bold">SUNDAY START:</span></p>
<dl>
<dt>1.</dt>
<dd>Take the first “active? [white] pill of the first pack on the <span class="Underline">Sunday after your period starts</span>, even if you are still <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span>. If your period begins on Sunday, start the pack that same day. </dd>
<dt>2.</dt>
<dd>
<span class="Underline">Use another method of birth control</span> as a back-up method if you have sex anytime from the Sunday you start your first pack until the next Sunday (7 days). Condoms, foam, or the sponge are good back-up methods of birth control. </dd>
</dl>
<p><span class="Bold">WHAT TO DO DURING THE MONTH</span></p>
<p><span class="Bold">1. TAKE ONE PILL AT THE SAME TIME EVERY DAY UNTIL THE PACK IS EMPTY.</span></p>
<p>Do not skip pills even if you are spotting or <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> between monthly periods or feel sick to your stomach (<span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>). </p>
<p>Do not skip pills even if you do not have sex very often.</p>
<p><span class="Bold">2. WHEN YOU FINISH A PACK OR SWITCH YOUR BRAND OF PILLS:</span></p>
<p><span class="Bold"><span class="Underline">21 pills</span></span>: Wait 7 days to start the next pack. You will probably have your period during that week. Be sure that no more than 7 days pass between 21-day packs. </p>
<p><span class="Bold"><span class="Underline">28 pills</span></span>: Start the next pack on the day after your last pill. Do not wait any days between packs. </p>
<p><span class="Bold">WHAT TO DO IF YOU MISS PILLS</span></p>
<p>If you <span class="Bold">MISS 1</span> “active? [white] pill:</p>
<dl>
<dt>1.</dt>
<dd>Take it as soon as you remember. Take the next pill at your regular time. This means you take 2 pills in 1 day.</dd>
<dt>2.</dt>
<dd>You do not need to use a back-up birth control method if you have sex.</dd>
</dl>
<p>If you <span class="Bold">MISS 2</span> “active? [white] pills in a row in <span class="Bold">WEEK 1 OR WEEK 2</span> of your pack:</p>
<dl>
<dt>1.</dt>
<dd>Take 2 pills on the day you remember and 2 pills the next day.</dd>
<dt>2.</dt>
<dd>Then take 1 pill a day until you finish the pack.</dd>
<dt>3.</dt>
<dd>You MAY BECOME PREGNANT if you have sex in the <span class="Bold"><span class="Underline">7 days</span></span> after you miss pills.</dd>
</dl>
<p>You MUST use another birth control method (such as condoms, foam, or sponge) as a back-up method for those 7 days.</p>
<p>If you <span class="Bold">MISS 2</span> “active? [white] pills in a row in <span class="Bold">WEEK 3</span>:</p>
<p>1. <span class="Bold"><span class="Italics">If you are a Day 1 Starter:</span></span></p>
<p>THROW OUT the rest of the pill pack and start a new pack that same day.</p>
<p><span class="Bold"><span class="Italics">If you are a Sunday Starter:</span></span></p>
<p>Keep taking 1 pill every day until Sunday.</p>
<p>On Sunday, THROW OUT the rest of the pack and start a new pack of pills that same day. </p>
<p>2. You may not have your period this month but this is expected. However, if you miss your period 2 months in a row, call your doctor or health care provider because you might be pregnant. </p>
<p>3. You MAY BECOME PREGNANT if you have sex in the <span class="Bold"><span class="Underline">7 days</span></span> after you miss pills. You MUST use another birth control method (such as condoms, foam, or sponge) as a back-up method for those 7 days. </p>
<p>If you <span class="Bold">MISS 3 OR MORE</span> “active? [white] pills in a row (during the first 3 weeks):</p>
<p>1. <span class="Bold"><span class="Italics">If you are a Day 1 Starter:</span></span></p>
<p>THROW OUT the rest of the pill pack and start a new pack that same day.</p>
<p><span class="Bold"><span class="Italics">If you are a Sunday Starter:</span></span></p>
<p>Keep taking 1 pill every day until Sunday.</p>
<p>On Sunday, THROW OUT the rest of the pack and start a new pack of pills that same day. </p>
<p>2. You may not have your period this month but this is expected. However, if you miss your period 2 months in a row, call your doctor or health care provider because you might be pregnant. </p>
<p>3. You MAY BECOME PREGNANT if you have sex in the <span class="Bold"><span class="Underline">7 days</span></span> after you miss pills. You MUST use another birth control method (such as condoms, foam, or sponge) as a back-up method for those 7 days. </p>
<p><span class="Bold">A REMINDER FOR THOSE ON 28-DAY PACKS </span></p>
<p>If you forget any of the 2 [green] or 5 [yellow] pills in Week 4:</p>
<p>THROW AWAY the pills you missed.</p>
<p>Keep taking 1 pill each day until the pack is empty.</p>
<p>You do not need a back-up method.</p>
<p><span class="Bold">FINALLY, IF YOU ARE STILL NOT SURE WHAT TO DO ABOUT THE PILLS YOU HAVE MISSED:</span></p>
<p>Use a BACK-UP METHOD anytime you have sex.</p>
<p>KEEP TAKING ONE “ACTIVE? [WHITE] PILL EACH DAY until you can reach your doctor or health care provider.</p>
<p><span class="Bold">PREGNANCY DUE TO PILL FAILURE</span></p>
<p>The incidence of pill failure resulting in pregnancy is approximately one percent (i.e., one pregnancy per 100 women per year) if taken every day as directed, but more typical failure rates are about 5%. If failure does occur, the risk to the fetus is minimal.</p>
<p><span class="Bold">PREGNANCY AFTER STOPPING THE PILL</span></p>
<p>There may be some delay in becoming pregnant after you stop using oral contraceptives, especially if you had <span class="product-label-link" type="condition" conceptid="196168" conceptname="Irregular periods">irregular menstrual cycles</span> before you used oral contraceptives. It may be advisable to postpone conception until you begin menstruating regularly once you have stopped taking the pill and desire pregnancy.</p>
<p>There does not appear to be any increase in <span class="product-label-link" type="condition" conceptid="4029540" conceptname="Congenital anomaly">birth defects</span> in newborn babies when pregnancy occurs soon after stopping the pill.</p>
<p><span class="Bold">OVERDOSAGE</span></p>
<p>Serious ill effects have not been reported following ingestion of large doses of oral contraceptives by young children. Overdosage may cause <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span> and <span class="product-label-link" type="condition" conceptid="4161407" conceptname="Withdrawal bleeding">withdrawal bleeding</span> in females. In case of overdosage, contact your doctor, health care provider or pharmacist.</p>
<p><span class="Bold">OTHER INFORMATION</span></p>
<p>Your doctor or health care provider will take a medical and family history before prescribing oral contraceptives and will examine you. The physical examination may be delayed to another time if you request it and your doctor or the health care provider believes that it is a good medical practice to postpone it. You should be reexamined at least once a year. Be sure to inform your doctor or health care provider if there is a family history of any of the conditions listed previously in this leaflet. Be sure to keep all appointments with your doctor or health care provider, because this is a time to determine if there are early signs of side effects of oral contraceptive use.</p>
<p>Do not use the drug for any condition other than the one for which it was prescribed. This drug has been prescribed specifically for you; do not give it to others who may want birth control pills.</p>
<p><span class="Bold">HEALTH BENEFITS FROM ORAL CONTRACEPTIVES</span></p>
<p>In addition to preventing pregnancy, use of combination oral contraceptives may provide certain benefits. They are: </p>
<dl>
<dt>•</dt>
<dd>menstrual cycles may become more regular. </dd>
<dt>•</dt>
<dd>blood flow during menstruation may be lighter and less iron may be lost. Therefore, <span class="product-label-link" type="condition" conceptid="439777" conceptname="Anemia">anemia</span> due to <span class="product-label-link" type="condition" conceptid="4146209" conceptname="Iron deficiency">iron deficiency</span> is less likely to occur. </dd>
<dt>•</dt>
<dd><span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span> or other symptoms during menstruation may be encountered less frequently. </dd>
<dt>•</dt>
<dd>ectopic (tubal) pregnancy may occur less frequently. </dd>
<dt>•</dt>
<dd>non-cancerous <span class="product-label-link" type="condition" conceptid="4209224" conceptname="Cyst">cysts</span> or lumps in the breast may occur less frequently. </dd>
<dt>•</dt>
<dd>acute <span class="product-label-link" type="condition" conceptid="199067" conceptname="Inflammatory disease of female pelvic organs AND/OR tissues">pelvic inflammatory disease</span> may occur less frequently. </dd>
<dt>•</dt>
<dd>oral contraceptive use may provide some protection against developing two forms of cancer: cancer of the ovaries and cancer of the lining of the uterus. </dd>
</dl>
<p>If you want more information about birth control pills, ask your doctor, health care provider, or pharmacist. They have a more technical leaflet called the Prescribing Information which you may wish to read.</p>
<p>Manufactured by:</p>
<p><span class="Bold">Glenmark Generics Ltd.</span></p>
<p>Colvale-Bardez, Goa 403 513, India </p>
<p>Manufactured for:</p>
<div class="Figure">
<a name="id13282125"></a><img alt="Glenmark logo" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=39988aa6-8f68-40e8-9bdd-c40a3bdaad61&amp;name=644dec7a-1c0d-4161-a454-e280023f5735-07.jpg">
</div>
<p><span class="Bold">Glenmark Generics Inc., USA</span></p>
<p>Mahwah, NJ 07430</p>
<p>Questions? 1 (888)721-7115</p>
<p>www.glenmarkgenerics.com</p>
<p>June 2013</p>
</div>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="i4i_Principal_display_panel_id_69abdf9a-7e1f-4809-bf3d-d8ecd135eb3e"></a><a name="section-16"></a><p></p>
<h1>PRINCIPAL DISPLAY PANEL</h1>
<div class="Figure">
<a name="id2069"></a><img alt="VIORELE carton" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=39988aa6-8f68-40e8-9bdd-c40a3bdaad61&amp;name=644dec7a-1c0d-4161-a454-e280023f5735-08.jpg">
</div>
<p class="First">NDC 68462-318-29     28 day Regimen</p>
<p>VIORELE</p>
<p>(Desogestrel and Ethinyl Estradiol Tablets USP, 0.15 mg/0.02 mg and Ethinyl Estradiol Tablets USP, 0.01 mg)</p>
<p>3 <span class="product-label-link" type="condition" conceptid="443720" conceptname="Blister">Blister</span> Cards each containing 28 tablets</p>
<p>RX ONLY</p>
<p>This product (like all oral contraceptives) is intended to prevent pregnancy. It does not protect against <span class="product-label-link" type="condition" conceptid="439727" conceptname="Human immunodeficiency virus infection">HIV infection</span> (AIDS) and other <span class="product-label-link" type="condition" conceptid="440647" conceptname="Sexually transmitted infectious disease">sexually transmitted diseases</span>.</p>
<p>Glenmark</p>
</div>
</div>
<div class="DataElementsTables">
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>VIORELE 		
					</strong><br><span class="contentTableReg">desogestrel and ethinyl estradiol and ethinyl estradiol kit</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:68462-318</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:68462-318-29</td>
<td class="formItem">3  in 1 CARTON</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem"></td>
<td class="formItem">1  in 1 <span class="product-label-link" type="condition" conceptid="443720" conceptname="Blister">BLISTER</span> PACK</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Quantity of Parts</td></tr>
<tr>
<th scope="col" width="5" class="formTitle">Part #</th>
<th scope="col" class="formTitle">Package Quantity</th>
<th scope="col" class="formTitle">Total Product Quantity</th>
</tr>
<tr class="formTableRowAlt">
<td width="5" class="formItem"><strong>Part 1</strong></td>
<td class="formItem"> </td>
<td class="formItem">21 </td>
</tr>
<tr class="formTableRow">
<td width="5" class="formItem"><strong>Part 2</strong></td>
<td class="formItem"> </td>
<td class="formItem">2 </td>
</tr>
<tr class="formTableRowAlt">
<td width="5" class="formItem"><strong>Part 3</strong></td>
<td class="formItem"> </td>
<td class="formItem">5 </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellspacing="0" cellpadding="5">
<tr><td class="contentTableTitle">Part 1 of 3</td></tr>
<tr><td class="contentTableTitle">
<strong>DESOGESTREL AND ETHINYL ESTRADIOL 		
					</strong><br><span class="contentTableReg">desogestrel and ethinyl estradiol tablet, film coated</span>
</td></tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt"></tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">ORAL</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">    
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>DESOGESTREL</strong> (DESOGESTREL) </td>
<td class="formItem">DESOGESTREL</td>
<td class="formItem">0.15 mg</td>
</tr>
<tr class="formTableRow">
<td class="formItem">
<strong>ETHINYL ESTRADIOL</strong> (ETHINYL ESTRADIOL) </td>
<td class="formItem">ETHINYL ESTRADIOL</td>
<td class="formItem">0.02 mg</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>.ALPHA.-TOCOPHEROL</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>STARCH, POTATO</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>POVIDONE K30</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>ISOPROPYL ALCOHOL</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>SILICON DIOXIDE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>MAGNESIUM STEARATE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>LACTOSE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>HYPROMELLOSES</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>TITANIUM DIOXIDE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>POLYETHYLENE GLYCOL 400</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>TALC</strong></td>
<td class="formItem"> </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Characteristics</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Color</td>
<td class="formItem">WHITE</td>
<td class="formLabel">Score</td>
<td class="formItem">no score</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Shape</td>
<td class="formItem">ROUND (biconvex) </td>
<td class="formLabel">Size</td>
<td class="formItem">5mm</td>
</tr>
<tr class="formTableRowAlt">
<td class="formLabel">Flavor</td>
<td class="formItem"></td>
<td class="formLabel">Imprint Code</td>
<td class="formItem">C1;G</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Contains</td>
<td class="formItem">    </td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">ANDA</td>
<td class="formItem">ANDA091346</td>
<td class="formItem">04/04/2012</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellspacing="0" cellpadding="5">
<tr><td class="contentTableTitle">Part 2 of 3</td></tr>
<tr><td class="contentTableTitle">
<strong>INERT 		
					</strong><br><span class="contentTableReg">inert tablet, film coated</span>
</td></tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt"></tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">ORAL</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">    
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>LACTOSE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>STARCH, CORN</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>MAGNESIUM STEARATE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>HYPROMELLOSES</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>TITANIUM DIOXIDE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>POLYETHYLENE GLYCOL 400</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>TALC</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>FERRIC OXIDE YELLOW</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>FD&amp;C BLUE NO. 2</strong></td>
<td class="formItem"> </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Characteristics</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Color</td>
<td class="formItem">GREEN</td>
<td class="formLabel">Score</td>
<td class="formItem">no score</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Shape</td>
<td class="formItem">ROUND (biconvex) </td>
<td class="formLabel">Size</td>
<td class="formItem">5mm</td>
</tr>
<tr class="formTableRowAlt">
<td class="formLabel">Flavor</td>
<td class="formItem"></td>
<td class="formLabel">Imprint Code</td>
<td class="formItem">C3;G</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Contains</td>
<td class="formItem">    </td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">ANDA</td>
<td class="formItem">ANDA091346</td>
<td class="formItem">04/04/2012</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellspacing="0" cellpadding="5">
<tr><td class="contentTableTitle">Part 3 of 3</td></tr>
<tr><td class="contentTableTitle">
<strong>ETHINYL ESTRADIOL 		
					</strong><br><span class="contentTableReg">ethinyl estradiol tablet, film coated</span>
</td></tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt"></tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">ORAL</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">    
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>ETHINYL ESTRADIOL</strong> (ETHINYL ESTRADIOL) </td>
<td class="formItem">ETHINYL ESTRADIOL</td>
<td class="formItem">0.01 mg</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>.ALPHA.-TOCOPHEROL</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>LACTOSE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>STARCH, POTATO</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>POVIDONE K30</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>ISOPROPYL ALCOHOL</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>SILICON DIOXIDE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>MAGNESIUM STEARATE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>HYPROMELLOSES</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>TITANIUM DIOXIDE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>POLYETHYLENE GLYCOL 400</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>TALC</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>FERRIC OXIDE YELLOW</strong></td>
<td class="formItem"> </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Characteristics</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Color</td>
<td class="formItem">YELLOW</td>
<td class="formLabel">Score</td>
<td class="formItem">no score</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Shape</td>
<td class="formItem">ROUND (biconvex) </td>
<td class="formLabel">Size</td>
<td class="formItem">5mm</td>
</tr>
<tr class="formTableRowAlt">
<td class="formLabel">Flavor</td>
<td class="formItem"></td>
<td class="formLabel">Imprint Code</td>
<td class="formItem">C2;G</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Contains</td>
<td class="formItem">    </td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">ANDA</td>
<td class="formItem">ANDA091346</td>
<td class="formItem">04/04/2012</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">ANDA</td>
<td class="formItem">ANDA091346</td>
<td class="formItem">04/04/2012</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite"><tr><td colspan="4" class="formHeadingReg">
<span class="formHeadingTitle">Labeler - </span>Glenmark Generics Inc., USA
							(130597813)
						</td></tr></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Establishment</span></td></tr>
<tr>
<th scope="col" class="formTitle">Name</th>
<th scope="col" class="formTitle">Address</th>
<th scope="col" class="formTitle">ID/FEI</th>
<th scope="col" class="formTitle">Business Operations</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">Glenmark Generics Limited</td>
<td class="formItem"></td>
<td class="formItem">677318665</td>
<td class="formItem">MANUFACTURE(68462-318), ANALYSIS(68462-318)</td>
</tr>
</table>
</div>
<p><div class="EffectiveDate">Revised: 9/2013<div class="DocumentMetadata">
<div>
<a href="javascript:toggleMixin();">Document Id: </a>644dec7a-1c0d-4161-a454-e280023f5735</div>
<div>Set id: 39988aa6-8f68-40e8-9bdd-c40a3bdaad61</div>
<div>Version: 6</div>
<div>Effective Time: 20130927</div>
</div>
</div> <div class="DistributorName">Glenmark Generics Inc., USA</div></p>
</body></html>
